An Open-label, Single-center, Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of RC48-ADC Combined With Pyrotinib in Local Advanced or Metastasis NSCLC With HER2 Mutation

This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation.

开始日期2027-12-01

申办/合作机构

荣昌生物制药（烟台）股份有限公司

NCT07892274

/ Not yet recruiting临床3期IIT

An Open-Label, Multicenter Clinical Study of Trastuzumab Rezetecan Followed by Pyrotinib in Combination With Fulvestrant and Dalpiciclib in Patients With HR-Positive, HER2-Positive Advanced Breast Cancer

The purpose of this clinical trial is to evaluate whether, in patients with hormone receptor-positive (HR-positive) and HER2-positive advanced breast cancer whose disease has progressed after trastuzumab-based therapy, switching to pyrotinib, fulvestrant, and dalpiciclib after induction with trastuzumab rezetecan-among those without disease progression-is superior to continued treatment with trastuzumab rezetecan. The three medicines are pyrotinib (a medicine that blocks HER2 and similar signals), fulvestrant (a hormone therapy), and dalpiciclib (a medicine that slows cancer cell division).
The primary question this study aims to answer is:
Does switching to pyrotinib, fulvestrant, and dalpiciclib prolong the time participants live without their cancer worsening compared with continued treatment with trastuzumab rezetecan?
The study will also assess overall survival, tumor response to treatment, and adverse events.
Researchers will compare the three-medicine combination with continued trastuzumab rezetecan.
Participants will:
Receive trastuzumab rezetecan once every 3 weeks for 6 cycles.
If the cancer has not worsened after these 6 cycles, be randomly assigned to receive either the three-medicine combination or continued trastuzumab rezetecan.
Undergo imaging scans every 6 weeks during the first 24 weeks and every 9 weeks thereafter to assess the cancer.
Undergo blood tests, cardiac assessments, and other safety evaluations during treatment and follow-up.

开始日期2026-11-01

申办/合作机构

中山大学孙逸仙纪念医院

NCT07836257

/ Not yet recruiting临床2期IIT

A Single-arm, Exploratory, Phase II Clinical Study of the Efficacy and Safety of Trastuzumab (T-DXd) in Combination With Pyrotinib in Patients Progressed After T-DXd Treatment for Advanced HER2-positive Breast Cancer

This is a single-arm, exploratory, phase II study evaluating the efficacy and safety of trastuzumab deruxtecan (T-DXd) in combination with pyrotinib in patients with HER2-positive advanced breast cancer whose disease has progressed after prior treatment with T-DXd.T-DXd is the established standard second-line therapy for HER2-positive advanced breast cancer. However, acquired resistance inevitably develops, and there is currently no approved standard treatment for patients progressing after T-DXd. Real-world studies report an objective response rate (ORR) of approximately 14.5% and a median progression-free survival of only 3 to 4 months in this setting, representing a major unmet medical need.Pyrotinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor that potently inhibits HER1, HER2 and HER4 kinase activity and blocks downstream PI3K/AKT and MAPK signaling. Preclinical and clinical data (including the HER2CLIMB-02 and TROPHY studies) support the synergistic potential of combining an anti-HER2 antibody-drug conjugate with a tyrosine kinase inhibitor.Participants receive T-DXd 5.4 mg/kg intravenously on Day 1 of each 21-day cycle plus pyrotinib 320 mg orally once daily, continuously, until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria. Tumor response is assessed using RECIST v1.1.The primary endpoint is objective response rate (ORR). Secondary endpoints include disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety/tolerability. Approximately 28 participants will be enrolled.

开始日期2026-10-10

申办/合作机构

福建医科大学

100 项与马来酸吡咯替尼相关的临床结果

登录后查看更多信息

100 项与马来酸吡咯替尼相关的转化医学

登录后查看更多信息

100 项与马来酸吡咯替尼相关的专利（医药）

登录后查看更多信息

442

项与马来酸吡咯替尼相关的文献（医药）

2027-01-01·Clinical and Translational Radiation Oncology

Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study

Article

作者: Mao, Dan ; Jing, Hao ; Chen, Zhengting ; Huang, Sheng ; Ma, Yuchao ; Chen, Xuesong ; Li, Lan ; Bi, Dongyu ; Yi, Junlin ; Zhou, Xinyan ; Lu, Shuang ; Wang, Miao ; Zhang, Ye ; Hou, Yu ; Xia, Yaoxiong

BACKGROUND AND PURPOSE:

Cranial radiotherapy (RT) and pyrotinib both demonstrate efficacy in HER2-positive breast cancer brain metastases (BCBM); however, the optimal sequencing of these modalities remains to be established. We evaluated survival across treatment sequences within a real-world cohort.

MATERIALS AND METHODS:

This retrospective, two-centre study included 101 patients with HER2-positive BCBM treated with cranial RT plus pyrotinib (June 2018-July 2025). Based on treatment sequence, patients were categorized into: concurrent RT and pyrotinib (Group A, n = 41); RT after intracranial progression on pyrotinib (Group B, n = 38); and pyrotinib upon progression following RT (Group C, n = 22). The primary endpoint was CNS-PFS. Survival outcomes were assessed via Kaplan-Meier estimation and Cox proportional hazards models.

RESULTS:

At a median follow-up of 43.3 months, 63 patients (62.4%) had died and 70 (69.3%) experienced CNS-PFS events. Median CNS-PFS was 14.8 months (95% CI 10.68-19.92) overall, and 14.3, 15.0, and 21.4 months in groups A, B, and C, respectively (P = 0.252); median OS was 36.0 months (95% CI 28.0-39.7) overall, and 33.0, 35.4, and 42.0 months in groups A, B, and C, respectively (P = 0.281). Focal cranial RT was independently associated with longer OS (HR 0.56, 95% CI 0.34-0.94; P = 0.028). Any-grade adverse events occurred in 100 of 101 patients (99.0%); grade ≥ 3 events occurred in 2.4%, 7.9%, and 4.5% of groups A, B, and C, respectively (all P > 0.05), and radiation necrosis occurred in 7 patients (6.9%). An exploratory threshold of RT initiated >3.9 months before pyrotinib (OS 49.9 vs 29.8 months; HR 0.31, 95% CI 0.11-0.91; P = 0.025) did not withstand internal validation.

CONCLUSIONS:

Treatment sequence did not significantly affect OS or CNS-PFS. Focal cranial RT was independently associated with longer survival, and toxicity was manageable. The proposed timing threshold is hypothesis-generating and warrants prospective validation.

2026-12-01·Materials Today Bio

Targeting an ASCL1–WNT11–ERK feed-forward loop to overcome pyrotinib resistance in HER2-positive breast cancer

Article

作者: Liu, Wei ; Li, Yingliang ; Wang, Yu ; Zhang, Zhanglin ; Liu, Zide ; Zeng, Qi ; Zhou, Boxuan ; Yu, Kuai ; Tang, Hong ; Zhu, Chao ; Mao, Xiaocheng ; Le, Aiping ; Gao, Chengqi ; Meng, Chuang ; Fan, Linwei ; Yin, Fang ; Liu, Hongfei ; Jiang, Alan ; Fu, Tianmei

Pyrotinib resistance remains a therapeutic obstacle in human epidermal growth factor receptor 2-positive (HER2⁺) breast cancer (BC), and tumor-selective strategies to restore drug response are lacking. Here, we identify ASCL1 as a mediator of pyrotinib resistance. ASCL1 was elevated in resistant cells and pretreatment tumors from pyrotinib-resistant patients. High ASCL1 expression was associated with shorter overall survival after adjustment for TNM stage. Mechanistically, ASCL1 promotes WNT11 transcription, thereby engaging non-canonical WNT11-ROR2 signaling to sustain ERK phosphorylation under pyrotinib treatment. Persistent ERK activity promotes CREB1 phosphorylation and p-CREB1 binding to the ASCL1 promoter and enhances its transcription, forming an ERK-CREB1-ASCL1-WNT11 feed-forward loop that reinforces resistance. To overcome this resistance program, we develop HApt-PEG-ZIF-8@siASCL1/Pyrotinib, a HER2 aptamer-guided ZIF-8 nanoplatform for tumor-selective co-delivery of ASCL1 siRNA and pyrotinib. This nanoplatform exhibits minimal hemolysis, enhanced uptake in HER2⁺ BC cells, prolonged circulation, and improved tumor delivery efficiency in vivo. Co-delivery suppresses ASCL1/WNT11 signaling and downstream p-ERK and p-CREB1, inhibits proliferation, migration, and invasion, induces apoptosis, and achieves robust antitumor efficacy in pyrotinib-resistant xenografts without detectable systemic toxicity. Together, this study reveals an ASCL1-driven resistance mechanism and establishes a HER2-targeted nanotherapeutic strategy to restore pyrotinib sensitivity, supporting ASCL1 as a therapeutic target in HER2⁺ BC.

2026-10-01·LUNG CANCER

First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial

Article

作者: Wei, Fang ; Xing, Puyuan ; Tian, Linyan ; Yang, Yaning ; Li, Weihua ; Jiang, Wenxin ; Hao, Xuezhi ; Lei, Siyu ; Yang, Guangjian ; Li, Junling ; Wang, Yan ; Xu, Haiyan

BACKGROUND:

Although emerging agents have broadened the therapeutic landscape for non-small cell lung cancer (NSCLC) harboring HER2 alterations, effective and accessible first-line therapy remains limited.

METHODS:

In this single-arm, phase II trial, treatment-naïve patients with stage IIIB-IV NSCLC harboring de novo HER2 mutations or amplification were given oral pyrotinib (400 mg) in combination with apatinib (250 mg) once daily until disease progression, intolerable toxicity, or death. The primary endpoint was overall response rate (ORR). Secondary endpoints consisted of disease control rate (DCR), progression-free survival (PFS), and safety.

RESULTS:

Between November 2021 and March 2024, 22 eligible patients were enrolled. The ORR was 72.7 % (95 % CI, 49.8-89.3), and the DCR reached 95.5 % (95 % CI, 77.2-99.9). With a median follow-up of 37.0 months (95 % CI, 36.1-37.9), the median PFS was 10.7 months (95 % CI, 6.6-14.8). Both patients harboring HER2 amplification achieved PFS exceeding 10 months, while the patient harboring HER2 exon 19 L755P mutation achieved a PFS exceeding 24 months. Grade 3-4 treatment-related adverse events occurred in 27.3 % of subjects, with diarrhea being the most prevalent (18.2 %). In the propensity score-matched analysis, pyrotinib plus apatinib prolonged PFS compared with chemotherapy-based regimens (robust standard error HR 0.53, 95 % CI: 0.34-0.81, P = 0.003). Circulating tumor DNA analysis demonstrated decreased HER2 variant allele frequency in 93.3 % of patients with paired baseline and post-C1 samples.

CONCLUSION:

Pyrotinib combined with apatinib demonstrated promising first-line activity, rapid responses, and manageable toxicity in advanced HER2-altered NSCLC, supporting its potential as an accessible chemotherapy-sparing therapy, particularly in resource-constrained settings.

1,719

项与马来酸吡咯替尼相关的新闻（医药）

2026-11-02

·网易号

成立165天的AI企业，被恒瑞“看上了”

撰稿｜武瑛港11月1日，根据企业官方信息，恒瑞医药与环保企业艾可蓝（300816.SZ）的控股子公司十方云（上海）科技有限公司（下称“十方云”）签署战略合作协议，双方将围绕AI赋能医药创新与全生命周期患者价值，建立长期战略合作关系。“患者全周期管理”和“真实世界数据治理”是这次合作的两个关键词。天眼查显示，十方云成立于2026年5月21日，成立至今共165天，不到6个月。此前10月27日，十方云与上海汇伦医药达成战略合作，4天后又拿下千亿市值恒瑞医药的合作。恒瑞在AI制药的前端靶点发现、分子生成、制剂优化等环节已经重点布局，为什么还要在这个时点，引入一个重点做真实世界数据与患者运营的合作方？十方云可能是恰好契合了恒瑞医药需要补齐的能力之一。从恒瑞医药三季报来看，BD收入是重要增长因素，但产品销售收入增速仅2.52%，后续能否持续盈利，不仅要看BD和在研管线，更要看已上市产品能不能在专利期内把患者价值做足，而十方云的价值可能正在于此。01.补齐AI版图在科研侧，双方围绕肿瘤、代谢和心血管疾病、免疫和呼吸系统疾病及神经科学等重点领域开展联合科研，推进临床及真实世界数据治理与结构化处理，为真实世界研究和循证医学证据生成提供支撑。在患者侧，探索“科研—患管”一体化模式，聚焦具有全周期管理需求的专病，在筛查、诊疗、随访、康复等环节用AI运营引擎提升科室、医生及患者管理效率。这次合作没有提到靶点和分子，而是聚焦临床之后、上市之后的环节。恒瑞医药重点布局这一环的原因，可能藏在最近公布的三季报里。2026年前三季度，恒瑞医药归母净利润69.23亿元，增长20.38%，BD收入是重要增长来源，主要是BMS的6亿美元首付款，第三季度单季净利润24.58亿元，同比增幅88.92%。但是从产品端来看，前三季度销售收入214.76亿元，增速2.52%。其中仿制药销售收入76.05亿元，同比下降16.41%；创新药销售收入138.71亿元，同比增长17.05%，扛大头的抗肿瘤创新产品收入98.65亿元，增速3.13%。恒瑞医药在三季报中表示，院内准入进度不及预期、部分上市较早的创新产品（如卡瑞利珠单抗、吡咯替尼等）竞争加剧，全年创新药销售收入增速与年初目标存在差距。当BD收入的确认节奏越来越难以预测，恒瑞医药要拉动利润增长，有两件事可能会越来越重要：把管线或新适应症顺利推进到下一个里程碑节点，以及让已上市的创新药在专利期内把患者价值做足。前者需要临床数据和真实世界证据来支撑，后者需要筛查、随访、康复各环节的患者管理来延长产品的收入爬坡曲线，这正是本次与十方云合作的内容。而且从靶点到分子再到制剂，恒瑞医药在药品研发前端已经有较为完整的布局，包括自研的灵枢AIDD平台、从法国Iktos签约引入的Makya™、部署的剂泰科技AiTEM人工智能制剂平台等。但在真实世界数据与患者管理上，据公开信息，恒瑞旗下数字医疗平台医朵云已有患者管理相关的AI工具布局，恒瑞与武汉大学中南医院的合作也将真实世界研究列入方向，但这些动作分散在子公司业务和医院合作层面，这次与十方云的合作可能正是为了补强此环节。02.一周两单合作，十方云做对了什么十方云与汇伦医药的合作在10月27日公布，5天后，恒瑞医药的签约消息落地。要理解十方云为什么能被连续选中，需要结合汇伦医药当前的处境。汇伦医药主营创新药和仿制药的研发、生产及销售，2026年4月递表港交所，招股书显示2023至2025年营收从9.85亿元降至6.86亿元，核心产品希为纳的收入也有所下滑。在新产品上市之前，汇伦医药需要守住现有产品的患者价值，十方云与其共建的“一体化AI科研患管平台”，落点或许正在此处。十方云能被连续选中，可能与其切入的AI环节有很大关系，不做靶点、不生成分子，而是专注药物进入临床之后、上市之后的环节，正好避开了当前AI制药明星企业的锋芒。另外是付费结构，例如与汇伦医药的合作，采用了“AI基建费用+动态算力消耗费用”的计费方式，基建费包含平台研发与培训实施等费用，算力费按灵析系列模型的Token消耗、数据洞察及Agent开发计量。药企的前期投入门槛被压低，对于一家成立不足半年的年轻AI公司而言，这种计费结构有助于降低药企的决策成本。另外值得关注的是，除了恒瑞医药，各大药企也在推进类似的AI布局。2026年10月，阿斯利康与Oracle（甲骨文）宣布全球AI合作，结合临床开发专长与真实世界数据、AI临床能力，目标是在药品全生命周期中持续生成证据。合作逻辑与恒瑞医药相近，但阿斯利康选择的是全球数据巨头。诺华则是开发了数字化患者服务项目“脂优小乐”，融合专业服务能力与AI创新技术，为高血脂患者提供疾病科普、自我管理和长期随访执行支持；辉瑞中国与镁信健康以多元支付为基石、AI与数据洞察为引擎，聚焦商保场景下的患者服务与运营提效。由此看来，AI+患者和真实世界数据也是大药企试水的方向之一。恒瑞此前在AI上的投入大多花在分子和制剂，这次把目光挪到患者和真实世界数据，能不能让已上市创新药在专利期里多释放一些价值，签约可能只是开始。*封面来源：AI生成秒追创新医药产业动态不遗漏一手信息推送！专题推荐声明：动脉新医药所刊载内容之知识产权为动脉新医药及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。文中如果涉及企业信息和数据，均由受访者向分析师提供并确认。点喜欢

财报专利到期引进/卖出

2026-11-02

·北京医学感染与传染研究

肝脏病学 84卷1-5期

Hepatology[Jour] AND 84[volume] AND 1[issue] 肝脏病学 84卷1期 https://journals.lww.com/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 Bile acids as the silent harbinger: Early signals of portal hypertension after “successful”Kasai 胆汁酸——沉默的预兆：Kasai术"成功"后的门脉高压早期信号 Sidhu, Guneet Hepatology. 84(1):1-2, July 2026. 2 What’s in a name? Reframing pediatric fatty liver disease in the Era of MASLD 名称之争：代谢相关脂肪性肝病（MASLD）时代儿童脂肪肝疾病的重新定义 Khalid, Mian B.; Ilyas, Sumera I. Hepatology. 84(1):3-4, July 2026. 3 One size does not fit all: Global variability in noninvasive testing for MASLD 一刀切不可取：MASLD无创检测的全球差异性 Erickson, Hanna Hepatology. 84(1):5-6, July 2026. 4 Good vibrations: Using VCTE to predict hepatic decompensation in MASLD 良好的振动：利用振动控制瞬时弹性成像（VCTE）预测MASLD患者的肝脏失代偿 Patel, Krishan S.; Arab, Juan Pablo Hepatology. 84(1):7-8, July 2026. Editorials（社论） 5 FIB-4 turns 20: A lesson of serendipity FIB-4二十周年：一次 serendipity（意外发现）的启示 Sterling, Richard K. Hepatology. 84(1):9-11, July 2026. 6 Cirrhotic portal vein thrombosis as a vascular rather than a thrombotic disorder 肝硬化门静脉血栓——一种血管性而非血栓性疾病 Huang, Xiaoquan; Lisman, Ton Hepatology. 84(1):12-14, July 2026. 7 From sex to size: Rethinking fairness in liver transplantation 从性别到体型：重新思考肝移植中的公平性 Rosenthal, Benjamin E.; Serper, Marina Hepatology. 84(1):15-16, July 2026. 8 Addressing the utility of a novel score for “at-risk” MASH in those with significant obesity 新型评分在显著肥胖人群中"高风险"代谢相关脂肪性肝炎（MASH）中的实用性探讨 Dillon, John F.; Leith, Damien; Brennan, Paul Hepatology. 84(1):17-19, July 2026. Original Articles（论著） Liver Cancer（肝脏肿瘤） 9 Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma 肿瘤部位影响MEKi联合免疫治疗在胆管癌临床前模型中的疗效 Hammons, Jacklyn N.; Warren, Emilie K.; Wittling, Megen C.; More Hepatology. 84(1):20-36, July 2026. 10 RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma RIPPLY1通过靶向TBX19抑制CTNNB1突变型肝细胞癌的肿瘤干细胞特性 Zhangyuan, Guangyan; Yu, Weiwei; Tian, Wenfang; More Hepatology. 84(1):37-56, July 2026. 11 Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7+CD8+ T-cell entry into HCC through high endothelial venules 抗血管生成治疗联合免疫检查点阻断通过高内皮微静脉促进CCR7+CD8+ T细胞进入HCC Tang, Lu; Hou, Yingwen; Di, Tian; More Hepatology. 84(1):57-73, July 2026. Liver Pathobiology（肝脏病理生物学） 12 Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p-pyroptosis axis 肝细胞来源的细胞外囊泡通过miR-153-3p-焦亡轴促进慢性肝病中的内皮去分化 Abad-Jordà, Laia; Andrés-Rozas, María; Martínez-Alcocer, Ana; More Hepatology. 84(1):74-90, July 2026. Liver Failure/Cirrhosis/Portal Hypertension（肝衰竭/肝硬化/门脉高压） 13 Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis 内皮-间充质转化：肝硬化门静脉血栓中可靶向的关键机制 Anton, Aina; Shalaby, Sarah; Botero, María Luisa; More Hepatology. 84(1):91-105, July 2026. 14 Sex and body size disparities under MELD 3.0: Evaluation of persisting gaps in liver transplant access MELD 3.0下的性别与体型差异：肝移植可及性中持续存在的差距评估 Tanaka, Tomohiro; Shane, Dan M.; Lai, Jennifer C. Hepatology. 84(1):106-116, July 2026. Pediatrics（儿科学） 15 Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia 血清胆汁酸水平可预测胆道闭锁Kasai术后成功患者门脉高压及高风险食管静脉曲张的发生 Grimaud, Emilie; Gardin, Antoine; Ackermann, Oanez; More Hepatology. 84(1):117-128, July 2026. 16 Reclassifying pediatric NAFLD using the steatotic liver disease framework: A multicenter retrospective study from the NASH CRN 利用脂肪性肝病框架重新分类儿童非酒精性脂肪性肝病（NAFLD）：来自NASH CRN的多中心回顾性研究 Lam, Tin Bo Nicholas; Yates, Katherine P.; Noon, Sheila L.; More Hepatology. 84(1):129-142, July 2026. Steatohepatitis（脂肪性肝炎） 17 KLF9 drives intermittent hypoxia-induced MASLD by suppressing the NR4A1–p38 MAPK hepatic metabolic axis KLF9通过抑制NR4A1–p38 MAPK肝脏代谢轴驱动间歇性缺氧诱导的MASLD Hua, Hongting; Wang, Dong; He, Lanqiaofeng; More Hepatology. 84(1):143-160, July 2026. 18 Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study MASLD无创检测的全球表现：来自G-MASLD研究的洞察 Younossi, Zobair M.; de Avila, Leyla; Petta, Salvatore; More Hepatology. 84(1):161-174, July 2026. 19 Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease 振动控制瞬时弹性成像与组织学在预测代谢功能障碍相关脂肪性肝病肝脏相关事件中的头对头比较 Zhang, Yangyue; Lee, Hye Won; Lin, Huapeng; More Hepatology. 84(1):175-190, July 2026. 20 Development and validation of a noninvasive score for at-risk metabolic dysfunction–associated steatohepatitis in individuals with obesity undergoing bariatric surgery 针对肥胖减重手术人群中"高风险"代谢功能障碍相关脂肪性肝炎的无创评分的开发与验证 Huang, Xin; Zhu, Tao; Li, Shumin; More Hepatology. 84(1):191-203, July 2026. Original Articles（论著） Steatohepatitis（脂肪性肝病） 21 Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study MASLD中纤维化、临床事件及死亡率的预测因素：来自Global-MASLD研究的数据 Younossi, Zobair M.; de Avila, Leyla; Petta, Salvatore; More Hepatology. 84(1):204-215, July 2026. Viral Hepatitis（病毒性肝炎） 22 HBV induces liver fibrosis through the generation of reactive oxygen species in a pyruvate-dependent manner 乙肝病毒（HBV）以丙酮酸依赖方式通过活性氧生成诱导肝纤维化 Duan, Xiaoqiong; Li, Shasha; Li, Qingyuan; More Hepatology. 84(1):216-232, July 2026. 23 IL1β signaling mediates the interaction between hepatitis B and C viruses IL1β信号介导乙型与丙型肝炎病毒之间的相互作用 Zhang, Fan; Zhao, Yuanyuan; Bian, Lu; More Hepatology. 84(1):233-250, July 2026. Reviews（综述） 24 Reprogramming macrophages to treat liver diseases 巨噬细胞重编码治疗肝脏疾病 Simón-Codina, Blanca; Cacho-Pujol, Júlia; Moles, Anna; More Hepatology. 84(1):251-272, July 2026. 25 Mechanisms coupling lipid droplets to MASLD pathophysiology 脂滴与MASLD病理生理偶联的机制 Reid, Mari V.; Fredickson, Gavin; Mashek, Douglas G. Hepatology. 84(1):273-291, July 2026. 26 Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic 新一代抗病毒药物与肥胖流行时代的肝癌预防 Suzuki, Hiroyuki; Fujiwara, Naoto; Singal, Amit G.; More Hepatology. 84(1):292-320, July 2026. Special Article（专题论著） 27 Non-invasive tests: Establishing efficacy for metabolic dysfunction–associated steatohepatitis beyond the biopsy—Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration 无创检测：在超越活检的层面确立代谢功能障碍相关脂肪性肝炎的有效性——来自美国食品药品监督管理局肝病与营养部的当前观点 Anania, Frank A.; Hager, Rebecca; Higgins, Karen; More Hepatology. 84(1):321-327, July 2026. Correspondence（读者来信） 28 Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 axis in CTNNB1-mutant hepatocellular carcinoma 致编辑信：重新评估RIPPLY1-TBX19轴在CTNNB1突变型肝细胞癌中的临床相关性 Zhang, Xiang; Gong, Hui; Gu, Kaikai; More Hepatology. 84(1):E1-E2, July 2026. 29 Letter to the Editor: Nuances in POCUS-guided hemodynamic assessment in cirrhosis 致编辑信：POCUS引导下肝硬化血流动力学评估中的细微之处 Koratala, Abhilash; Argaiz, Eduardo R. Hepatology. 84(1):E3-E4, July 2026. 30 Reply: Nuances in POCUS-guided hemodynamic assessment in cirrhosis 回复：POCUS引导下肝硬化血流动力学评估中的细微之处 Premkumar, Madhumita; Kajal, Kamal Hepatology. 84(1):E5-E6, July 2026. 31 Letter to the Editor: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children? 致编辑信：PNPLA3悖论——基因型是否改变MASLD框架在儿童中的临床实用性？ Liu, Boyan; Li, Heran Hepatology. 84(1):E7-E8, July 2026. 32 Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children? 回复：PNPLA3悖论——基因型是否改变MASLD框架在儿童中的临床实用性？ Lam, Tin Bo Nicholas; Goyal, Nidhi P.; Newton, Kimberly P.; More Hepatology. 84(1):E9-E10, July 2026. 33 Letter to the Editor: The profile of HBsAg levels after nucleos(t)ide analogues treatment is crucial for achieving a functional cure 致编辑信：核苷（酸）类似物治疗后HBsAg水平的变化特征对实现功能性治愈至关重要 Tang, Qiao; Hu, Peng Hepatology. 84(1):E11-E12, July 2026. 34 Letter to the Editor: Comments on the Study—Body size disparities limit women’s access to liver transplantation under the MELD 3.0 scoring system 致编辑信：对"体型差异限制女性在MELD 3.0评分体系下获得肝移植机会"研究的评论 He, Jiahang; Xie, Qing; Cao, Zhujun Hepatology. 84(1):E13, July 2026. 35 Letter to the Editor: Clarifying validation and statistical aspects of AI-based risk prediction in liver disease 致编辑信：澄清AI基于风险预测在肝病中的验证与统计学问题 Liu, Jing; Zhang, Guo-Ming Hepatology. 84(1):E14-E15, July 2026. 36 Reply: Clarifying validation and statistical aspects of AI-based risk prediction in liver disease 回复：澄清AI基于风险预测在肝病中的验证与统计学问题 Zhang, Peng; Su, Grace L. Hepatology. 84(1):E16-E17, July 2026. 37 Letter to the Editor: Clarifying endothelial specificity and hemodynamic coupling of the miR-153-3p–pyroptosis axis 致编辑信：澄清miR-153-3p–焦亡轴的内皮特异性与血流动力学偶联 Weng, Dandan Hepatology. 84(1):E18-E19, July 2026. 38 Letter to the Editor: Placebo drift, dose heterogeneity, and the winner’s curse—Re-evaluating the hierarchy of MASH therapeutics 致编辑信：安慰剂漂移、剂量异质性与赢者诅咒——重新评估MASH治疗药物的层级 Philips, Cyriac Abby; Oommen, Tharun Tom; Ahamed, Rizwan Hepatology. 84(1):E20-E21, July 2026. 39 Reply: Placebo drift, dose heterogeneity, and the winner’s curse—Re-evaluating the hierarchy of MASH therapeutics 回复：安慰剂漂移、剂量异质性与赢者诅咒——重新评估MASH治疗药物的层级 Souza, Matheus; Huang, Daniel Q.; Loomba, Rohit Hepatology. 84(1):E22-E23, July 2026. 40 Letter to the Editor: Interpreting the clinical decision value of glycomic-based models for early HCC detection in CHB 致编辑信：解读糖组学模型在CHB早期HCC检测中的临床决策价值 Jiang, Qing-Bao; Zhang, Guo-Ming Hepatology. 84(1):E24-E25, July 2026. 41 Letter to the Editor: From weight to waist—Refining fibrosis prediction in the Global MASLD cohort 致编辑信：从体重到腰围——优化Global MASLD队列中的纤维化预测 Zeng, Hong; Huang, Xi Hepatology. 84(1):E26-E27, July 2026. 42 Reply: From weight to waist—Refining fibrosis prediction in the Global MASLD cohort 回复：从体重到腰围——优化Global MASLD队列中的纤维化预测 Stepanova, Maria; Younossi, Zobair M. Hepatology. 84(1):E28-E29, July 2026. Hepatology[Jour] AND 84[volume] AND 2[issue] 肝脏病学 84卷2期 https://journals.lww.com/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 PSC’s itch is worth scratching: Pruritus can be more than a symptom 原发性硬化性胆管炎瘙痒值得重视：瘙痒并非单纯伴随症状 Yigit Yazarkan Hepatology. August 2026: 84(2):329-330 2 The weight of progress: Why dynamic weight trajectories matter in MASLD 体重变化的临床意义：代谢相关脂肪性肝病中动态体重轨迹的价值 Guneet Sidhu Hepatology. August 2026: 84(2):331-332 3 The liver joins the CKM conversation: Fibrosis risk across the cardiometabolic spectrum 肝脏纳入心脏代谢疾病评估：横跨心脏代谢疾病谱的肝纤维化风险 Omar Albhaisi, Juan Pablo Arab Hepatology. August 2026: 84(2):333-334 4 Pizza versus Pi*ZZ: The metabolic amplifiers in alpha-1 antitrypsin deficiency 饮食与基因交互：α1-抗胰蛋白酶缺乏症的代谢放大因素 John Grady, Juan Pablo Arab Hepatology. August 2026: 84(2):335-336 Editorials（社论） 5 Stains in primary biliary cholangitis: Untangling promise from bias 原发性胆汁性胆管炎相关染色标志物：区分临床价值与研究偏倚 Therese Bittermann, Charles E. Leonard Hepatology. August 2026: 84(2):337-339 6 Multiomics and machine learning in cholangiocarcinoma: A paradigm shift toward molecular subtyping and precision therapy 多组学与机器学习在胆管癌中的应用：迈向分子分型与精准治疗的范式革新 Meng Xu, Ju-Seog Lee Hepatology. August 2026: 84(2):340-342 7 A targeted liver cancer therapy independent of immune checkpoint block 不依赖免疫检查点抑制剂的肝癌靶向治疗方案 Bangyan L. Stiles Hepatology. August 2026: 84(2):343-345 8 Alcohol use dominates determining liver-related events in steatotic liver disease: Rethinking the role of metabolic dysfunction 饮酒是脂肪性肝病肝脏不良事件的核心诱因：重新审视代谢功能障碍的作用 Luis Antonio Díaz, Winston Dunn, Ashwani K. Singal Hepatology. August 2026: 84(2):346-348 9 Shedding new light on the chicken-and-egg dilemma of hepatitis delta virus (HDV) replication initiation 厘清丁型肝炎病毒复制起始的因果先后难题 Julie Lucifora, Francesco Negro Hepatology. August 2026: 84(2):349-352 Original Articles: Immune-Mediated Diseases, DILI, and Biliary Tract Disease（论著：免疫介导性肝病、药物性肝损伤与胆道疾病） 10 Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study 原发性硬化性胆管炎瘙痒高发且持续存在，瘙痒程度与疾病严重度相关：一项多中心前瞻性观察研究 Nasir Hussain, Rodrigo V. Motta, Usha Gungabissoon, Linda Casillas, Sumanta Mukherjee, Andrea Ribeiro, Megan M. Mclaughlin, Kaitlin Hagan, Khushpreet Bhandal, Penelope Rogers, Martine Walmsley, James Ferguson, Andreas E. Kremer, Emma L. Culver, Palak J. Trivedi Hepatology. August 2026: 84(2):353-366 11 Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study 他汀类药物使用与原发性胆汁性胆管炎患者肝失代偿的关联：模拟目标临床试验研究 Jonggi Choi, Junqing Xu, Vy H. Nguyen, Eric Przybyszewski, Daniel S. Pratt, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung Hepatology. August 2026: 84(2):367-377 Original Articles: Liver Cancer（论著：肝脏肿瘤） 12 NEK7-induced phosphorylation of EGFR on serine 1070 drives the acquired lenvatinib resistance in hepatocellular carcinoma NEK7介导EGFR第1070位丝氨酸磷酸化诱发肝细胞癌的仑伐替尼获得性耐药 Qibo Huang, Weijian Wang, Qianyun Ge, Dafeng Xu, Renshun Dong, Ruizhi Chang, Xing Wu, Jie Mo, Chen Su, Deng Ning, Qiumeng Liu, Huifang Liang, Guihua Wang, Jin Chen, Xifeng Fu, Xiaoping Chen, Junnan Liang, Bixiang Zhang Hepatology. August 2026: 84(2):378-395 13 Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target 多组学联合机器学习鉴定胆管癌独特分子亚型并筛选TNK1为治疗靶点 Dong-Gi Mun, Erik Jessen, Jennifer L. Tomlinson, Danielle Carlson, Rohit Budhraja, Roberto Alva-Ruiz, Amro Abdelrahman, Ryan Watkins, Lindsey Gregory, Chantal McCabe, Chen Wang, Rondell P. Graham, Kathryn Woods, Martin Golkowski, Marshall Baker, Gregory J. Gores, Sumera I. Ilyas, Caitlin Conboy, Ellen L. Larson, Jack W. Sample, Enis H. Ozmert, Richard K. Kandasamy, Mitesh J. Borad, Lewis Roberts, Joshua Andersen, Akhilesh Pandey, Rory L. Smoot Hepatology. August 2026: 84(2):396-410 14 Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy 病毒性与代谢相关脂肪性肝病相关肝癌肠道菌群存在差异，但代谢组特征趋同，共同影响联合免疫治疗疗效 Pei-Chang Lee, Chi-Jung Wu, Ya-Wen Hung, Chieh-Ju Lee, Hsien-Chen Mon, Chen-Ta Chi, I-Cheng Lee, Yu-Lun Kuo, Shih-Hsuan Chou, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang Hepatology. August 2026: 84(2):411-423 15 Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles 载聚肌胞苷酸脂质纳米颗粒可有效抑制肝脏原发及转移性肿瘤 Yingluo Liu, Xinyi Wang, Nishta Krishnan, Timothy Hsiao, Yichun Ji, Kota Kaneko, Marcos G. Teneche, Peter D. Adams, Elina Zuniga, Susan M. Kaech, Liangfang Zhang, Gen-Sheng Feng Hepatology. August 2026: 84(2):424-439 16 Genomic and transcriptomic profiling of hepatocellular carcinoma in patients with Fontan-associated liver disease 丰坦手术相关性肝病合并肝细胞癌的基因组与转录组图谱分析 Taiji Yamazoe, Eiji Kakazu, Michitaka Matsuda, Masaaki Mino, Taizo Mori, Sachiyo Yoshio, Yuriko Tsutsui, Takashi Motomura, Shinji Itoh, Koichiro Haruki, Kenei Furukawa, Shinichiro Yamada, Takeshi Takamoto, Takehiro Noda, Hidetoshi Eguchi, Kiyoshi Hasegawa, Yuji Morine, Toru Ikegami, Tomoharu Yoshizumi, Tatsuya Kanto Hepatology. August 2026: 84(2):440-452 17 Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy 深度学习辅助MRI肿瘤影像组学动态特征预测免疫治疗联合肝切除肝细胞癌患者的病理完全缓解 Shi-Qi Zhou, Lu-Na Wang, Li-Fang Wu, Li-Yu Sun, Yu-Chen Yang, Zi-Yue Yang, Zi-Yi Wang, Tian He, Fei Li, Ling-Li Chen, Hui Li, Xiao-Dong Zhu, Ying-Hao Shen, Cheng Huang, Yuan Ji, Qiang Gao, Jian Zhou, Jia Fan, Yong-Jun Chen, Tian-Qiang Song, Bin Xu, Hui-Chuan Sun Hepatology. August 2026: 84(2):453-468 Original Articles: Liver Pathobiology（论著：肝脏病理生物学） 18 Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation 肝细胞FoxO1表观遗传抑制破坏肝脏局部免疫稳态并诱发肝炎症 Zhigang Lei, Yu Wu, Weijie Xue, Dongmei Zhu, Junyao Shen, Chenxu Mao, Ziling Wang, Chuanhong Huang, Yuxin Zhang, Jifeng Zhu, Lei Xu, Yalin Li, Xiujun Zhang, Shouguo Liu, Xiaojun Chen, Chunyan Ye, Sha Zhou, Chuan Su Hepatology. August 2026: 84(2):469-486 19 CXCR6 defines a distinct resident state in γδ T cells for protecting from liver cirrhosis CXCR6标记具有独特定居表型的γδT细胞，可抵御肝硬化进展 Jiahao Ji, Zhitao Chen, Wenjing He, Yanxu Chen, Dongmei Ye, Yingqian Zhong, Xiaomin Shi, Xiaojun Ouyang, Zhimin Zeng, Qianyu Ye, Xiaoshun He, Zhinan Yin, Jianlei Hao, Yifang Gao Hepatology. August 2026: 84(2):487-502 Original Articles: Steatohepatitis（论著：脂肪性肝炎） 20 Differential associations of cardiometabolic risk factors with liver-related events by alcohol consumption category: Results from a large population-based study 不同饮酒分层下心代谢危险因素与肝脏不良事件的差异性关联：一项大样本人群研究 Hongliang Xue, Liqing Wang, Yuankai Wu, Yingxin Liao, Shijia Wang, Ailan Chen, Sun On Chan, Wenhua Ling, Xu Chen, Chao Yu Hepatology. August 2026: 84(2):503-513 21 Association between longitudinal weight change and clinical outcome in individuals with MASLD 代谢相关脂肪性肝病患者纵向体重变化与临床预后的相关性 Yu Shi, Ruoqi Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen, Philip Noel Newsome, Jian-Gao Fan, Michelle Lai, Laurent Castéra, Céline Fournier-Poizat, Hye Won Lee, Grace Lai-Hung Wong, Grazia Pennisi, Masato Yoneda, Ying Shang, Angelo Armandi, Marc de Saint-Loup, Clemence M. Canivet, Kevin Kim-Jun Teh, Amon Asgharpour, Rocio Gallego-Durán, Elba Llop, Carmen Lara-Romero, Mandy Sau-Wai Chan, Mirko Zoncape, Huapeng Lin, Wen-Yue Liu, Giovanni Targher, Christopher D. Byrne, Vincent Wai-Sun Wong, Ming-Hua Zheng, Hepatology. August 2026: 84(2):514-528 22 Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD 心肾代谢综合征与代谢相关脂肪性肝病肝纤维化进展及肝脏不良事件风险的关联 Xiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen, Laurent Castéra, Arun J. Sanyal, George Boon-Bee Goh, Philip Noel Newsome, Jian-Gao Fan, Michelle Lai, Céline Fournier-Poizat, Hye Won Lee, Grace Lai-Hung Wong, Angelo Armandi, Ying Shang, Grazia Pennisi, Elba Llop, Masato Yoneda, Marc de Saint-Loup, Clemence M. Canivet, Paloma Carrillo-Fernandez, Carmen Lara-Romero, Rocio Gallego-Durán, Amon Asgharpour, Kevin Kim-Jun Teh, Mandy Sau-Wai Chan, Huapeng Lin, Wen-Yue Liu, Giovanni Targher, Christopher D. Byrne, Vincent Wai-Sun Wong, Ming-Hua Zheng, Hepatology. August 2026: 84(2):529-541 23 Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency α1-抗胰蛋白酶缺乏症中遗传与代谢危险因素的协同放大效应 Christina Schrader, Malin Fromme, Paul Ellis, Audrey Payancé, Mattias Mandorfer, Jan Stolk, Bart van Hoek, Katrine H. Thorhauge, Monica Pons, Marc Miravitlles, Guido Stirnimann, Sona Frankova, Jan Sperl, Andreas E. Kremer, Katharina Remih, Emily K. Weber, Lorenz Balcar, Annelot D. Sark, Benedikt Schaefer, Joanna Chorostowska-Wynimko, Elmar Aigner, Sophie Gensluckner, Heike Bantel, Jef Verbeek, Zoe Mariño, Rohit Loomba, Heinz Zoller, Michael Trauner, Joan Genesca, Virginia Clark, Aleksander Krag, Noel G. McElvaney, William J. Griffiths, Alice M. Turner, Pavel Strnad Hepatology. August 2026: 84(2):542-558 Original Articles: Viral Hepatitis（论著：病毒性肝炎） 24 CDK8 and CDK19 Mediator kinases are required for hepatitis delta virus replication 中介激酶CDK8与CDK19是丁型肝炎病毒复制的必需分子 Angga Prawira, Mattis Hilleke, Mengqian Chen, Igor B. Roninson, Ralf Bartenschlager, Stephan Urban, Yi Ni Hepatology. August 2026: 84(2):559-572 Reviews（综述） 25 Unmet needs in diagnosis and management of portopulmonary hypertension: How far have we reached? 门脉性肺动脉高压诊疗尚未满足的临床需求：当前研究进展综述 Michael J. Krowka, Hilary M. DuBrock, Sarah Raevens, Michael B. Fallon Hepatology. August 2026: 84(2):573-581 26 Getting to HBV cure—Will new biomarkers help? 迈向乙型肝炎治愈：新型生物标志物能否提供助力？ Jordan J. Feld, Adam J. Gehring, Fabien Zoulim Hepatology. August 2026: 84(2):582-600 Special Articles（专题论著） 27 A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF 多学会关于门窦血管病变/非肝硬化性门脉高压新统一定义与诊断标准的共识声明 Virginia Hernandez-Gea, Valerie Paradis, Maha Guindi, Venancio A.F. Alves, Amal Aqul, Eira Cerda, Sarwa Darwish Murad, Prasenjit Das, Angelo Di Giorgio, Luiz A.R. de Freitas, Tassos Grammatikopoulos, Kenichi Harada, Nelia Hernandez, Samar H. Ibrahim, Sanjay Kakar, Saul Karpen, David E. Kleiner, Necati Ormeci, Xiaolong Qi, Puja Sakhuja, Maria Isabel Schinoni, Romil Saxena, Alexandre Sayadi, Akash Shukla, Dina G. Tiniakos, Elizabeth Verna, Kerry Wong, Laure Elkrief, Christine Sempoux, Theo Heller, Pierre-Emmanuel Rautou Hepatology. August 2026: 84(2):601-616 28 Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH Ⅱb期临床试验证实依鲁西佛明在不同PNPLA3基因型代谢相关脂肪性肝炎人群中疗效稳定 Naga Chalasani, Erik J. Tillman, Sonja K. Billes, Timothy Rolph, Mazen Noureddin Hepatology. August 2026: 84(2):617-620 Correspondence（通信） 29 Letter to the Editor: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy? 致编者信：粪便乙酸盐是否可作为全病因肝癌免疫治疗疗效预测标志物？ Zhou Zhao, Jian Sun, Qiuhong You, Zhixian Lan, Yinghong Zhu Hepatology. August 2026: 84(2):E30-E31 30 Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy? 回复：粪便乙酸盐是否可作为全病因肝癌免疫治疗疗效预测标志物？ Pei-Chang Lee, Yi-Hsiang Huang Hepatology. August 2026: 84(2):E32-E33 31 Letter to the Editor: Survival analysis pitfalls in MASLD: Proportional hazards, immortal time, and follow-up discrepancies 致编者信：代谢相关脂肪性肝病生存分析常见误区：比例风险、永生时间与随访偏差 Jian Huang Hepatology. August 2026: 84(2):E34-E35 32 Reply: Survival analysis pitfalls in MASLD—Proportional hazards, immortal time, and follow-up discrepancies 回复：代谢相关脂肪性肝病生存分析常见误区——比例风险、永生时间与随访偏差 Yu Shi, Ruoqi Zhou, Yuanjie Pang, Vincent Wai-Sun Wong, Ming-Hua Zheng Hepatology. August 2026: 84(2):E36-E37 33 Letter to the Editor: Beyond Semantics—Acknowledging diagnostic differences between NAFLD and MASLD 致编者信：不止命名差异——正视NAFLD与MASLD的诊断区分要点 Giovani Schulte Farina, Jonathan Soldera Hepatology. August 2026: 84(2):E38-E39 34 Reply: Beyond semantics—Acknowledging diagnostic differences between NAFLD and MASLD 回复：不止命名差异——正视NAFLD与MASLD的诊断区分要点 Madalina-Gabriela Indre, Federico Ravaioli Hepatology. August 2026: 84(2):E40-E41 35 Letter to the editor: Deep learning and digital pathology for HCC prediction in steatotic liver disease 致编者信：深度学习与数字病理用于脂肪性肝病肝癌发生风险预测 Luisa Giudice, Stefano Granieri, Stefania Galassi, Sante De Santis, Emmanuel Pio Pastore Hepatology. August 2026: 84(2):E42-E43 36 Reply: Deep learning and digital pathology power prediction of HCC development in steatotic liver disease 回复：深度学习联合数字病理可精准预测脂肪性肝病患者肝癌发病风险 Takuma Nakatsuka, Ryosuke Tateishi, Masaya Sato, Kazuhiko Koike Hepatology. August 2026: 84(2):E44-E45 Errata（勘误） 37 Erratum: Reciprocal regulation between forkhead box M1/NF-κB and methionine adenosyltransferase 1A drives liver cancer 勘误：FOXM1/NF-κB与甲硫氨酸腺苷转移酶1A相互调控促进肝癌发生 Yuan Li, Liqing Lu, Jian Tu, Jing Zhang, Ting Xiong, Wei Fan, Jiaohong Wang, Meng Li, Yibu Chen, Justin Steggerda, Hui Peng, Yongheng Chen, Tony WH Li, Zhi-Gang Zhou, José M Mato, Ekihiro Seki, Ting Liu, Heping Yang, Shelly C. Lu Hepatology. August 2026: 84(2):E46-E47 38 Erratum: AlphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma 勘误：αB-晶状体蛋白结合14-3-3ζ诱导肝细胞癌上皮间质转化与索拉非尼耐药 Huang Xiao-Yong, Ke Ai-Wu, Shi Guo-Ming, Zhang Xin, Zhang Chi, Shi Ying-Hong, Wang Xiao-Ying, Ding Zhen-Bin, Xiao Yong-Sheng, Yan Jun, Qiu Shuang-Jian, Fan Jia, Zhou Jian Hepatology. August 2026: 84(2):E48-E49 39 Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis 勘误：美国肝病研究协会慢加急性肝衰竭与重症肝硬化患者管理临床实践指南 Constantine J. Karvellas, Jasmohan S. Bajaj, Patrick S. Kamath, Lena Napolitano, Jacqueline G. O’Leary, Elsa Solà, Ram Subramanian, Florence Wong, Sumeet K. Asrani Hepatology. August 2026: 84(2):E50-E50 40 Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D 勘误：非侵入性评估非酒精性脂肪性肝病合并2型糖尿病患者肝病严重程度 Grazia Pennisi, Marco Enea, Vincenzo Falco, Guruprasad P. Aithal, Naaventhan Palaniyappan, Yusuf Yilmaz, Jerome Boursier, Christophe Cassinotto, Victor de Lédinghen, Wah Kheong Chan, Sanjiv Mahadeva, Peter Eddowes, Philip Newsome, Thomas Karlas, Johannes Wiegand, Vincent Wai-Sun Wong, Jörn M. Schattenberg, Christian Labenz, Won Kim, Myoung Seok Lee, Monica Lupsor-Platon, Jeremy F. Cobbold, Jian-Gao Fan, Feng Shen, Katharina Staufer, Michael Trauner, Rudolf Stauber, Atsushi Nakajima, Masato Yoneda, Elisabetta Bugianesi, Ramy Younes, Silvia Gaia, Ming-Hua Zheng, Calogero Cammà, Quentin M. Anstee, Ferenc E. Mózes, Michael Pavlides, Salvatore Petta Hepatology. August 2026: 84(2):E51-E51 Retraction（撤稿声明） 41 Retraction: HSP72 interacts with PRDX6 to deubiquitinate mitochondrial PINK1, activating mitophagy to treat MASLD 撤稿声明：热休克蛋白72结合过氧化物还原蛋白6去泛素化线粒体PINK1，激活线粒体自噬改善代谢相关脂肪性肝病 Yong Rao, Rui Su, Wen-jie Cao, Yue Chen, Shu-heng Huang, Jun-jie Wu, Darren C. Henstridge, Lin-sheng Huang, Jin Liu, Fei-fei Liu, Zhong-ping Jiang, Cong-jun Xu, Zhi-shu Huang, Ji-ming Ye, Ling Huang Hepatology. August 2026: 84(2):E52-E52 Hepatology[Jour] AND 84[volume] AND 3[issue] 肝脏病学 84卷3期 https://journals.lww.com/hep/pages/currenttoc.aspx Hepatology Highlights（《肝脏病学》重点导读） 1 The road less traveled: Mapping the complex trajectories of PSC‑IBD 少有人走的路：原发性硬化性胆管炎‑炎症性肠病复杂病程轨迹解析 Mian B. Khalid Hepatology. September 2026: 84(3):621‑622 2 One cancer, four personalities: Transcriptomic signatures reveal molecular subtypes of advanced biliary tract cancer 一种肿瘤，四种表型：转录组特征揭示晚期胆道癌分子亚型 Muhammed Dogukan Aksu Hepatology. September 2026: 84(3):623‑624 3 Hepatic footprint of emerging antihyperglycemic therapies 新型降糖治疗的肝脏效应 P. Vineeth Daniel Hepatology. September 2026: 84(3):625‑626 4 No prescription needed: Remote nutrition care linked to fewer liver events 无需处方：远程营养干预可减少肝脏相关不良事件 Leandro Sierra, Juan Pablo Arab Hepatology. September 2026: 84(3):627‑628 Fellows' Corner（青年学者园地） 5 Fellows’ Corner 青年学者园地 Somaya Albhaisi Hepatology. September 2026: 84(3):629‑630 Editorials（社论） 6 Population‑level screening for liver disease: Opportunities and challenges 人群水平肝脏疾病筛查：机遇与挑战 Pedro Ochoa‑Allemant, Marina Serper Hepatology. September 2026: 84(3):631‑633 7 Two decades of hepatitis E in solid organ transplantation: From endemic insight to unresolved therapeutic questions 实体器官移植中戊型肝炎二十年：从流行特征到尚未解决的治疗难题 Patrick Behrendt, Christoph Neumann‑Haefelin Hepatology. September 2026: 84(3):634‑637 8 Interpreting surgical associations in primary sclerosing cholangitis: Caution in clinical messaging 解读原发性硬化性胆管炎的手术相关性：临床解读需审慎 Bregje Mol, Palak J. Trivedi Hepatology. September 2026: 84(3):638‑640 Original Articles: Immune‑Mediated Diseases, DILI, and Biliary Tract Disease（论著：免疫介导性疾病、药物性肝损伤与胆道疾病） 9 Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes 他汀类药物通过重编程囊胆管上皮细胞代谢、恢复线粒体生物能量功能抑制多囊肝进展 Enara Markaide, Laura Izquierdo‑Sanchez, Irene Olaizola, Josu Urretabizkaia‑Garmendia, Mikel Ruiz de Gauna, Xabier Buqué, Irune Lasa‑Elosegi, Ainhoa Lapitz, Thomas Bais, Beatriz Val, Pedro M. Rodrigues, Rui E. Castro, Maria J. Perugorria, Luis Bujanda, Ron Gansevoort, Joost P.H. Drenth, Patricia Aspichueta, Jesus M. Banales Hepatology. September 2026: 84(3):641‑657 10 Understanding hepatopancreatobiliary cancer risks in a population‑based primary sclerosing cholangitis–inflammatory bowel disease cohort 基于人群的原发性硬化性胆管炎‑炎症性肠病队列肝胆胰肿瘤风险研究 Kristel K. Leung, Wenbin Li, Bettina Hansen, Aliya Gulamhusein, Lauren Lapointe‑Shaw, Amanda Ricciuto, Eric I. Benchimol, Jennifer A. Flemming, Gideon M. Hirschfield Hepatology. September 2026: 84(3):658‑671 Original Articles: Liver Cancer（论著：肝脏肿瘤） 11 GPC3‑based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses 基于GPC3的环状RNA疫苗通过激活适应性免疫应答抑制肝细胞癌进展 Yifan Jiang, Yu Li, Tong Wu, Linping Cao, Guangming Xu, Jiwei Liu, Chenguang Hua, Chaofeng Ding, Beng Yang, Rongliang Tong, Diyu Chen, Jian Wu Hepatology. September 2026: 84(3):672‑689 12 Laser‑activated nanoparticles rewire tumor microenvironment enhancing PD‑1 blockade and T cell response in cholangiocarcinoma 激光激活纳米颗粒重编程肿瘤微环境增强胆管癌PD‑1阻断疗效与T细胞应答 Mirko Minini, Giulio Avveduto, Sonia Becharef, Marie Meunier‑Thaens, Bouchra Lekbaby, Maria Perez‑Lazon, Alice Machado, Thomas Guilbert, Julie Lesieur, Gilles Renault, Sara Ceccacci, Ida Chiara Guerrera, Christophe Klein, Jérémy Augustin, Rana Bazzi, Stephane Roux, Jonathan Pol, Emmanuel Donnadieu, Florence Gazeau, Laura Fouassier Hepatology. September 2026: 84(3):690‑707 13 FXR splicing by SF3B3 promotes MYC‑driven hepatocarcinogenesis SF3B3介导FXR可变剪接促进MYC驱动的肝细胞癌发生 Xue Wang, Jiahua Luo, Lifeng Han, Tong Xu, Haichuan Wang, Mingzhe Zhang, Gen Li, Xichuan Li, Weihua Zhang, Youcai Zhang Hepatology. September 2026: 84(3):708‑725 14 Biology‑driven stratification of advanced biliary tract cancer treated with nab‑paclitaxel plus gemcitabine–cisplatin: A prospective observational cohort study 白蛋白结合型紫杉醇联合吉西他滨‑顺铂治疗晚期胆道癌的生物学分层：一项前瞻性观察队列研究 Seonjeong Woo, Beodeul Kang, Sung Hwan Lee, Jung Sun Kim, Haeyoun Kang, Seok Jeong Yang, Chansik An, Gwangil Kim, Gae Hoon Jo, Chang‑Il Kwon, Min Je Sung, Suk Pyo Shin, Sanghoon Jung, Sohyun Hwang, Chan Kim, Hong Jae Chon Hepatology. September 2026: 84(3):726‑739 15 Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling 多灶性肝内胆管癌卫星灶与肝内转移：预后价值及基因组特征分析 Tao Wei, Zhi‑Jie Ma, Shouliang Guo, Matthew Weiss, Irinel Popescu, Hugo P. Marques, Luca Aldrighetti, Shishir K. Maithel, Carlo Pulitano, Todd W. Bauer, Feng Shen, George A. Poultsides, Oliver Soubrane, Guillaume Martel, Bas Groot Koerkamp, Itaru Endo, Tingbo Liang, Yi Lyu, Timothy M. Pawlik, Xu‑Feng Zhang, Hepatology. September 2026: 84(3):740‑755 16 Long‑term outcomes of atezolizumab–bevacizumab in unresectable hepatocellular carcinoma: A real‑world study 阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的远期预后：一项真实世界研究 Francesco Tovoli, Massimo Iavarone, Giuseppe Cabibbo, Fabio Marra, Caterina Vivaldi, Andrea Dalbeni, Francesca Romana Ponziani, Andrea Palloni, Francesca Bergamo, Lorenza Rimassa, Lorenzo Lani, Piera Federico, Gianluca Svegliati‑Baroni, Luca Ielasi, Chiara Mazzarelli, Stefania De Lorenzo, Rodolfo Sacco, Mariangela Bruccoleri, Ciro Celsa, Alessio Mastro, Gianluca Masi, Alessandra Auriemma, Leonardo Stella, Pierluigi Toniutto, Rosanna Villani, Sara Lonardi, Tiziana Pressiani, Fabio Piscaglia, Hepatology. September 2026: 84(3):756‑768 Original Articles: Liver Pathobiology（论著：肝脏病理生物学） 17 Hepatic STEAP4 promotes liver regeneration by regulating lysosomal iron homeostasis and membrane integrity in acetaminophen‑induced liver injury 肝脏STEAP4通过调控溶酶体铁稳态及膜完整性促进对乙酰氨基酚肝损伤后的肝再生 Peng Cao, Mengwei Niu, Hualong Zhu, Chen Zhang, Hao Zhu, Hangfei Xu, Wanqing Liu, Hong‑Min Ni, Wen‑Xing Ding Hepatology. September 2026: 84(3):769‑784 18 ECM1 produced by hepatic stellate cells serves as a gatekeeper of liver homeostasis in hepatic fibrosis 肝星状细胞分泌ECM1是肝纤维化中肝脏稳态的关键调控因子 Aiting Yang, Xuzhen Yan, Yiwen Wang, Qi Han, Xiaofei Tong, Shuyan Chen, Xinyu Zhao, Wei Chen, Jidong Jia, Detlef Schuppan, Hong You Hepatology. September 2026: 84(3):785‑804 Original Articles: Liver Failure/Cirrhosis/Portal Hypertension（论著：肝衰竭/肝硬化/门静脉高压） 19 LiverRisk score (LRS) predicts long‑term liver‑related outcomes in a cohort of Veterans without evidence of liver disease LiverRisk评分（LRS）可预测无肝病证据退伍军人队列的长期肝脏相关预后 Ruben Hernaez, Yan Liu, Miquel Serra‑Burriel, Kavish R. Patidar, Adrià Juanola, Isabel Graupera, Elisa Pose, Núria Fabrellas, Avegail G. Flores, Jennifer R. Kramer, Fasiha Kanwal, Pere Gines Hepatology. September 2026: 84(3):805‑816 Original Articles: Steatohepatitis（论著：脂肪性肝炎） 20 Real‑world impact of AUD pharmacotherapy on healthcare utilization, cost, and cost‑effectiveness in the United States 美国酒精使用障碍药物治疗对医疗资源利用、费用及成本效益的现实影响 Chi M. Nguyen, Hanna L. Blaney, Jing Su, Shihui Jiang, Yang Li, Yining Li, Samer Gawrieh, Wanzhu Tu, Suthat Liangpunsakul Hepatology. September 2026: 84(3):817‑832 21 Repurposing Resmetirom suppresses MASH‑associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1‑mediated metabolic reprogramming and immunosuppression Resmetirom老药新用抑制MASH相关肝细胞癌：MDK/LRP1介导代谢重编程与免疫抑制的机制研究 Vanilla Xin Zhang, Tina Suoangbaji, Yu‑Man Tsui, Karen Man‑Fong Sze, Eva Lee, Lu Tian, Jingyi Lu, Huan Deng, Abdullah Husain, Charry Shuk‑Ching Hui, Joyce Man‑Fong Lee, Daniel Wai‑Hung Ho, Irene Oi‑Lin Ng Hepatology. September 2026: 84(3):833‑850 22 Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta‑analysis of data from 5.3 million patients with type 2 diabetes mellitus 新型降糖药物对肝脏并发症的影响：基于530万2型糖尿病患者数据的系统综述与Meta分析 Jiwon Yang, Yeongseok Hwang, Jin‑Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim Hepatology. September 2026: 84(3):851‑869 23 Reduced risk of liver‑related events among patients receiving individualized nutrition‑focused remote care in the United States 美国接受个体化营养导向远程照护患者的肝脏相关事件风险降低 Shaminie J. Athinarayanan, Adam J. Wolfberg, Priya V. Shanmugam, Bilal A. Hameed, Maurizio Bonacini Hepatology. September 2026: 84(3):870‑885 Original Articles: Viral Hepatitis（论著：病毒性肝炎） 24 T‑ and B‑cell–targeting DNA/MVA HCV vaccines induce strong and broad cellular and humoral immunity in mice and rhesus macaques 靶向T、B细胞的DNA/MVA丙型肝炎疫苗在小鼠与恒河猴体内诱导强效广谱细胞及体液免疫 Sheikh Abdul Rahman, Sailaja Gangadhara, John Gridley, Uchurappa Mala, Elizabeth J. Elrod, Nathalie Bédard, Julie Bruneau, Naglaa H. Shoukry, Arash Grakoui, Rama Rao Amara Hepatology. September 2026: 84(3):886‑899 25 Two decades of hepatitis E in solid organ transplantation: A retrospective monocentric analysis 实体器官移植中戊型肝炎二十年：单中心回顾性分析 Nassim Kamar, Florence Abravanel, Olivier Marion, Chloé Couat, Laure Esposito, Anne Laure Hebral, Laurence Lavayssière, David Ribes, Pierre Guy, Sébastien Lhomme, Olivier Cointault, Stanislas Faguer, Julie Bellière, Amandine Darres, Joelle Guitard, Chloé Médrano, Arnaud Del Bello, Jacques Izopet Hepatology. September 2026: 84(3):900‑909 Reviews（综述） 26 Portal sinusoidal vascular diseases: Assessment and therapy 门窦血管性疾病：评估与治疗 Maria Mironova, Harish Gopalakrishna, Christopher Koh, David E. Kleiner, Theo Heller Hepatology. September 2026: 84(3):910‑931 27 Assessment of liver injury potential of investigational medicines in drug development 药物研发过程中候选药物肝损伤风险评估 Naga Chalasani, Paul H. Hayashi, Debra Luffer‑Atlas, Arie Regev, Paul B. Watkins Hepatology. September 2026: 84(3):932‑951 28 Advances in imaging—Elastography 影像学进展——弹性成像 Elton Dajti, Adrian T. Huber, Giovanna Ferraioli, Annalisa Berzigotti Hepatology. September 2026: 84(3):952‑975 29 Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications 肝星状细胞异质性：功能特征与治疗价值 Yana Geng, Robert F. Schwabe Hepatology. September 2026: 84(3):976‑989 Special Article（专题论著） 30 Integrative Hepatology: Enhancing overall health to manage liver disease 整合肝病学：通过改善整体健康管理肝脏疾病 Jennifer C. Lai, Elliot B. Tapper, Puneeta Tandon Hepatology. September 2026: 84(3):990‑998 Position Paper（立场文件） 31 AASLD‑EASL Delphi consensus statement on surrogate endpoints and real‑world evidence in primary biliary cholangitis AASLD‑EASL关于原发性胆汁性胆管炎替代终点与现实证据德尔菲共识声明 American Association for the Study of Liver Diseases,European Association for the Study of the Liver Hepatology. September 2026: 84(3):999‑1024 Correspondence（读者来信） 32 Letter to the Editor: Clarifying the relative contributions of collagen architecture and stiffness to antitumor immunity in GIONF‑Enhanced PD‑1 blockade for cholangiocarcinoma 致编辑的信：阐明胶原结构与硬度在GIONF增强PD‑1阻断治疗胆管癌中对抗肿瘤免疫的相对作用 Dandan Weng, Guancheng Huang, Yingying Liu Hepatology. September 2026: 84(3):E53‑E54 33 Letter to the Editor: Hepatocyte‑derived extracellular vesicles promote endothelial pyroptosis in chronic liver disease: Undefined role of miR‑153‑3p 致编辑的信：肝细胞来源胞外囊泡促进慢性肝病内皮细胞焦亡：miR‑153‑3p作用尚不明确 Xinyi Hu, Qi Zhang, Lulu Wan, Mengyang Liu Hepatology. September 2026: 84(3):E55‑E56 Errata（勘误） 34 Erratum: NK‑cell–elicited gasdermin‑D–dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitate HBV‑related acute‑on‑chronic liver failure 勘误：NK细胞诱导GSDMD依赖的肝细胞焦亡促进中性粒细胞胞外网状陷阱形成参与乙肝相关慢加急性肝衰竭 Qiang Zhao, Dong‑Ping Chen, Hua‑Di Chen, Ying‑Zhe Wang, Wei Shi, Yi‑Tong Lu, Yi‑Zheng Ren, Yuankai Wu, Yi‑Hua Pang, Hong Deng, Xiaoshun He, Dong‑Ming Kuang, Zhiyong Guo Hepatology. September 2026: 84(3):E57‑E59 35 Erratum: RNF128 aggravates metabolic dysfunction–associated steatotic liver disease progression via stabilization of SCD1 勘误：RNF128通过稳定SCD1加重代谢功能障碍相关脂肪性肝病进展 Lei Cao, Wei Yang, Chaofan Wang, Changhao Liu, Wenqian Qi, Ruiqing Ren, Jie Zhang, Shuting Yu, Qian Li, Liangyu Cai, Xinyu Zhang, Xiaohong Wang, Wenhai Sui, Meng Zhang, Cheng Zhang Hepatology. September 2026: 84(3):E60‑E60 Hepatology[Jour] AND 84[volume] AND 4[issue] 肝脏病学 84卷4期 https://journals.lww.com/hep/pages/currenttoc.aspx Reviews（综述） 1 Response evaluation to systemic therapy in HCC: Current challenges and future perspectives 肝细胞癌全身治疗的疗效评估：当前挑战与未来展望 Mario Matute-González, Maxime Ronot, Victoria Chernyak, Bruno Sangro, Jordi Rimola Hepatology. October 2026: 84(4):1025-1048 2 Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma 开创精准时代：肝细胞癌免疫治疗的发展历程 Friedrich Foerster, Lucas Wiesmann, Paula Bark, Peter Robert Galle Hepatology. October 2026: 84(4):1049-1077 3 Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma 二线治疗之外：晚期肝细胞癌全身治疗的序贯策略 Marta Fortuny, Landon L. Chan, Leonardo G. da Fonseca, Ghassan K. Abou-Alfa, Stephen L. Chan, María Reig Hepatology. October 2026: 84(4):1078-1095 4 Clinical utilization of testing for cell-free DNA in hepatocellular cancer 游离DNA检测在肝细胞癌中的临床应用 Jasmine J. Wang, Yi-Te Lee, Amy K. Kim, Augusto Villanueva, Amit G. Singal, Ju Dong Yang Hepatology. October 2026: 84(4):1096-1120 5 Incorporating artificial intelligence into imaging for surveillance and diagnosis of liver cancer: Innovations, challenges, and clinical translation 人工智能融入肝癌筛查与诊断影像：创新、挑战与临床转化 Maxime Ronot, Julien Calderaro Hepatology. October 2026: 84(4):1121-1132 6 Anatomic subsets of cholangiocarcinoma: More different than alike 胆管癌解剖亚型：共性有限，差异显著 Yawen Dong, Hannah E. Stumpf, Rory L. Smoot, Patrick P. Starlinger, Mark M. Yarchoan, Gregory J. Gores, Sumera I. Ilyas Hepatology. October 2026: 84(4):1133-1156 7 Evolving precision: Updates in targeted therapy for cholangiocarcinoma 精准治疗持续进展：胆管癌靶向治疗新进展 Giulia Tesini, Halima Ibrahim, Lorenza Rimassa, Chiara Braconi Hepatology. October 2026: 84(4):1157-1180 8 The rise of transplant oncology in primary liver cancer and metastatic disease 移植肿瘤学在原发性肝癌及转移性疾病中的兴起 Charles-Henri Wassmer, Maximiliano Gelli, Tiffany Cho Wong, Zhihao Li, Anudari Zorigtbaatar, Rebecca Marino, Laia Aceituno Sierra, René Adam, Albert Chi Chan, Julie Heimbach, Pål Dag Line, Vincenzo Mazzaferro, Gonzalo Sapisochin, Parissa Tabrizian, Arndt Vogel, Christian Toso Hepatology. October 2026: 84(4):1181-1208 9 Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma 纤维板层癌诊疗临床指南 Allison F. O’Neill, Emily L. Zeme, Ghassan K. Abou-Alfa, Marina Baretti, Alexander J. Bondoc, Alanna Church, Cristina R. Ferrone, Megan Fitzgerald, James I. Geller, Anne E. Gill, William P. Harris, Heung Bae Kim, Sunyoung S. Lee, Kevin X. Liu, Michael V. Ortiz, Arun Rangaswami, Kimberly J. Riehle, Abby R. Rosenberg, Michael S. Torbenson, Mark Yarchoan, John D. Gordan Hepatology. October 2026: 84(4):1209-1228 10 Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer 破解肿瘤图谱：肝细胞癌多组学与空间生物学研究启示 Dawiyat Massoudi, Ankit Srivastava, Renumathy Dhanasekaran Hepatology. October 2026: 84(4):1229-1245 Hepatology[Jour] AND 84[volume] AND 5[issue] 肝脏病学 84卷5期 https://journals.lww.com/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 A gentler squeeze: A first signal from OCE-205, a selective V1a mixed agonist–antagonist for hepatorenal syndrome–acute kidney injury 温和调控：选择性V1a混合激动-拮抗剂OCE-205用于肝肾综合征合并急性肾损伤的初步研究结果 Prowpanga Udompap Hepatology. November 2026: 84(5):1247-1248 2 Present but not prescient: Cardiometabolic risk factors in alcohol-associated hepatitis 存在但不具备预测价值：酒精相关性肝炎的心代谢危险因素 Enis H. Ozmert Hepatology. November 2026: 84(5):1249-1250 3 Turning down the ammonia dial: Phase 2a evidence for YAQ007 in cirrhosis 下调血氨水平：YAQ007用于肝硬化的2a期临床证据 Hanna Erickson Hepatology. November 2026: 84(5):1251-1252 4 Rethinking albumin after paracentesis: It’s not just about the volume 重新审视腹腔穿刺术后白蛋白应用：不只是容量问题 Kevin Houston, Juan Pablo Arab Hepatology. November 2026: 84(5):1253-1254 Editorials（社论） 5 Radiomics beyond the visible—Decoding tumor heterogeneity to guide combination therapy of intermediate-stage HCC 超越可视影像的放射组学——解析肿瘤异质性指导中期肝细胞癌联合治疗 William Lotter, Julius Chapiro Hepatology. November 2026: 84(5):1255-1257 6 Metabolic reprogramming in macrophages: A glutamine rescue in β-catenin mutant hepatocellular carcinoma 巨噬细胞代谢重编程：β-连环蛋白突变型肝细胞癌中的谷氨酰胺代偿机制 Gregory Kenneth Muliawan, Terence Kin Lee Hepatology. November 2026: 84(5):1258-1261 7 Unraveling the immunogenetic architecture of cholangiocarcinoma 解析胆管癌的免疫遗传结构 Claudia Wing-Kwan Wu, Rashid N. Lui Hepatology. November 2026: 84(5):1262-1263 8 Hepatocellular carcinoma with macrovascular invasion: Navigating heterogeneous evidence 合并大血管侵犯的肝细胞癌：梳理异质性研究证据 Manon Allaire, Irene Bargellini Hepatology. November 2026: 84(5):1264-1266 9 B-BEST: Profiling the intrahepatic HBV reservoir at single-cell resolution B-BEST研究：单细胞水平解析肝内乙肝病毒储存库特征 Armando Andres Roca Suarez, Barbara Testoni, Fabien Zoulim Hepatology. November 2026: 84(5):1267-1269 Original Articles: Immune-Mediated Diseases, DILI, and Biliary Tract Disease（论著：免疫介导性疾病、药物性肝损伤与胆道疾病） 10 Liver transcriptome sequencing contributes to the molecular diagnosis of genetic liver diseases 肝脏转录组测序助力遗传性肝病的分子诊断 Ye Cheng, Zhong-Die Li, Zhi-Hong Guan,et al. Hepatology. November 2026: 84(5):1270-1285 Original Articles: Liver Cancer（论著：肝脏肿瘤） 11 Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma 靶向固醇O-酰基转移酶1重编程脂肪酸代谢并揭示肝细胞癌的免疫脆弱点 Huanhuan Ma, Vanilla Xin Zhang, Yu Man Tsui, et al. Hepatology. November 2026: 84(5):1286-1302 12 Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204) 基于影像生物标志物解析肿瘤异质性预测肝细胞癌经动脉化疗栓塞联合免疫及靶向治疗疗效（CHANCE2204研究） Zhi-Cheng Jin, Jingwei Wei, Yu-Dong Xiao, et al. Hepatology. November 2026: 84(5):1303-1316 13 Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming β-连环蛋白突变肝细胞癌中谷氨酰胺合成酶缺失通过巨噬细胞代谢重编程促进肿瘤负荷增加 Evan R. Delgado, Panari Patel, Junyan Tao, et al. Hepatology. November 2026: 84(5):1317-1334 14 Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses 通过全基因组关联研究及整合分析揭示胆管癌及其亚型的遗传图谱 Younghun Han, Jinyoung Byun, Caitlin J. VanLith, et al. Hepatology. November 2026: 84(5):1335-1351 15 Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole 第二代抗精神病药阿立哌唑用于肝细胞癌的化学预防 Nevena Slović, Sumit Mishra, Subhojit Paul, et al. Hepatology. November 2026: 84(5):1352-1370 16 Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria 合并大血管侵犯肝细胞癌：基于简易预后标准的初始局部治疗综述及生存Meta分析 Marta Fortuny, Antonio De Rosa, Ignacio Roca, et al. Hepatology. November 2026: 84(5):1371-1380 17 Hepatectomy alters adjuvant anti–PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy 肝切除术改变肝细胞癌小鼠模型中辅助抗PD-1的作用，但不影响新辅助治疗疗效 Roqiya Bouguerra, Sofia El Hajji, Charles-Henri Wassmer, et al. Hepatology. November 2026: 84(5):1381-1395 Original Articles: Liver Pathobiology（论著：肝脏病理生物学） 18 Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophages 髓系细胞CD36缺失通过增强巨噬细胞适应性免疫减轻肝纤维化 Liangyun Li, Yilong Fang, Jintong Zhang, et al. Hepatology. November 2026: 84(5):1396-1414 Original Articles: Liver Failure/Cirrhosis/Portal Hypertension（论著：肝衰竭/肝硬化/门静脉高压） 19 Featured video: Complications of chronic liver disease 精选视频：慢性肝病并发症 Jacqueline G. O’Leary Hepatology. November 2026: 84(5):E61-E61 20 Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study 门诊腹腔穿刺术后静脉输注白蛋白降低急性肾损伤住院风险：一项全国队列研究 Nadim Mahmud, Max S. Schechter, Siqi Zhang, et al. Hepatology. November 2026: 84(5):1415-1425 21 OCE-205, a selective V1a receptor mixed agonist–antagonist, for the treatment of hepatorenal syndrome–acute kidney injury: A phase 2 randomized trial 选择性V1a受体混合激动-拮抗剂OCE-205治疗肝肾综合征合并急性肾损伤：一项2期随机试验 Andrew S. Allegretti, Giuseppe Cullaro, Paul Kwo, et al. Hepatology. November 2026: 84(5):1426-1436 22 A randomized, open-label, phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis 评估YAQ007与利福昔明用于肝硬化的安全性、药效学及药代动力学的随机开放2a期研究 Maria Pilar Ballester, Juan Antonio Carbonell-Asins, Ahmed Elshabrawi, et al. Hepatology. November 2026: 84(5):1437-1450 Original Articles: Steatohepatitis（论著：脂肪性肝炎） 23 Age and sex influence transcriptomic responses to statin therapy that control liver aging during systemic metabolic dysfunction 年龄与性别影响他汀治疗的转录组应答，调控全身代谢异常状态下的肝脏衰老 David S. Umbaugh, Liuyang Wang, Kuo Du, et al. Hepatology. November 2026: 84(5):1451-1468 24 Hepatic GPR75 exacerbates MASH through GNAI2-dependent signaling 肝脏GPR75通过GNAI2依赖信号通路加重代谢相关脂肪性肝炎 Xule Yang, Na Yang, Zhihao Cheng, et al. Hepatology. November 2026: 84(5):1469-1485 25 Longitudinal assessment of the circulating cytokine profile of severe alcohol-associated hepatitis 重症酒精相关性肝炎循环细胞因子谱的纵向评估 David Tornai, Mack C. Mitchell, Craig J. McClain, et al. Hepatology. November 2026: 84(5):1486-1502 26 Exploring the interaction between metabolic dysfunction and alcohol-associated hepatitis: A global study 探讨代谢异常与酒精相关性肝炎的相互作用：一项全球性研究 Vania Cari, María I. Perez, Ignacio Tellez, et al. Hepatology. November 2026: 84(5):1503-1513 Original Articles: Viral Hepatitis（论著：病毒性肝炎） 27 A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B 甲磺酸普拉德福韦对比富马酸替诺福韦酯治疗中国慢性乙型肝炎患者的随机双盲3期非劣效试验 Yanhang Gao, Xinrui Wang, Zhongfeng Wang, et al. Hepatology. November 2026: 84(5):1514-1528 28 Host-viral interaction of HBV infection revealed by single-cell transcriptome jointly profiling the viral replication state 联合病毒复制状态的单细胞转录组分析揭示乙肝病毒感染的宿主-病毒相互作用 Yanfang Huang, Hongyuan Xue, Jinhang He, et al. Hepatology. November 2026: 84(5):1529-1547 Reviews（综述） 29 Detecting at-risk steatotic liver disease and liver fibrosis in the community 社区高危脂肪性肝病及肝纤维化筛查 Leon A. Adams, Maja Thiele, Emmanuel A. Tsochatzis Hepatology. November 2026: 84(5):1548-1566 30 Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease 细胞治疗与肝脏类器官构建技术：终末期肝病的潜力治疗策略 Shaoyang Qin, Xiaochen Bo, Hongyuan Liu, et al. Hepatology. November 2026: 84(5):1567-1586 Special Article（专题论著） 31 Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium 肝细胞癌风险分层模型的构建与验证：转化肝癌研究联盟提出的框架 Fasiha Kanwal, Ziding Feng, Yujin Hoshida, et al. Hepatology. November 2026: 84(5):1587-1604 Correspondence（通信） 32 Letter to the Editor: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC 致编辑信：手术时机影响肝细胞癌肝切除术后辅助PD-1治疗疗效 Yanyu Zhang, Yehao Zhang, Tingting Hu Hepatology. November 2026: 84(5):E62-E63 33 Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC 回复：手术时机影响肝细胞癌肝切除术后辅助PD-1治疗疗效 Roqiya Bouguerra, Sofia El Hajji, Charles Wassmer, et al. Hepatology. November 2026: 84(5):E64-E65 34 Letter to the Editor: Methodological considerations for ITH quantification and model integration 致编辑信：肿瘤内异质性定量及模型整合的方法学考量 Zhengtong Zhou, Hua Zhou Hepatology. November 2026: 84(5):E66-E67 35 Letter to the Editor: The suggestion for additional clinical scores in decoding tumor heterogeneity in HCC 致编辑信：对解析肝细胞癌肿瘤异质性增设临床评分的建议 Jixu Guo, Shuiping Yu Hepatology. November 2026: 84(5):E68-E68 36 Reply: The suggestion for additional clinical scores in decoding tumor heterogeneity in HCC 回复：对解析肝细胞癌肿瘤异质性增设临床评分的建议 Zhi-Cheng Jin, Gao-Jun Teng Hepatology. November 2026: 84(5):E69-E69 Errata（勘误） 37 Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study 勘误：代谢相关脂肪性肝病无创检测的全球效能——G-MASLD研究启示 Zobair M. Younossi, Leyla de Avila, Salvatore Petta, et al. Hepatology. November 2026: 84(5):E70-E71 38 Erratum: Pathogenic Ifit1+ neutrophils driven by IRF7 promote liver injury and represent a therapeutic target in acute liver failure 勘误：IRF7介导的致病性Ifit1阳性中性粒细胞加重肝损伤，是急性肝衰竭的治疗靶点 Yu Lu, Yi Zhang, Lina Sun, Fangyuan Gao, et al. Hepatology. November 2026: 84(5):E72-E72 39 Erratum: H19 promotes HCC bone metastasis through reducing osteoprotegerin expression in a protein phosphatase 1 catalytic subunit alpha/p38 mitogen-activated protein kinase-dependent manner and sponging microRNA 200b-3p 勘误：H19通过蛋白磷酸酶1催化亚基α/p38丝裂原活化蛋白激酶通路下调骨保护素并吸附微小RNA 200b-3p，促进肝细胞癌骨转移 Zhao Huang, Liang Chu, Junnan Liang, et al. Hepatology. November 2026: 84(5):E73-E74 40 Erratum: GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes 勘误：GLP-1受体激动剂联合SGLT-2抑制剂对合并2型糖尿病的代谢相关脂肪性肝病成人严重肝脏及心血管不良事件风险的影响 Xianhua Mao, Hong Fan, Man-Fung Yuen, et al. Hepatology. November 2026: 84(5):E75-E75 41 Erratum: Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma 勘误：CD151与/或c-Met过表达在肝细胞癌预后预测中的价值 Ai-Wu Ke, Guo-Ming Shi, Jian Zhou, et al. Hepatology. November 2026: 84(5):E76-E78

临床结果

2026-11-01

·终身学习-星辰如梦

【药品分享】甲磺酸瑞齐替尼胶囊——第三代EGFR酪氨酸激酶抑制剂（EGFR-TKI）

甲磺酸瑞齐替尼胶囊（瑞必达®，Rezivertinib，BPI-7711）是上海倍而达药业研发的国产1类创新药、第三代EGFR-TKI，靶向EGFR敏感突变与T790M耐药突变，血脑屏障穿透强、脑转移获益显著。2024年获批二线（T790M）与一线（19del/L858R），已进国家医保。基本信息药物类型：小分子化药，第三代EGFR酪氨酸激酶抑制剂（EGFR-TKI）原研/研发机构：上海倍而达药业有限公司（Beta Pharma，1类创新药自主立项研发）；化合物专利由倍而达（贝达医药公司/Beta Pharma Inc）持有。靶点：EGFR（表皮生长因子受体）酪氨酸激酶——同时靶向EGFR敏感突变（外显子19缺失、L858R）与一/二代TKI耐药突变T790M，并选择性抑制突变型、保留野生型EGFR。作用机制：瑞齐替尼是不可逆、高选择性的第三代EGFR-TKI，不可逆共价结合EGFR突变体激酶域ATP结合位点，阻断下游RAS/RAF/MEK/ERK（MAPK）、PI3K/AKT/mTOR、JAK/STAT等增殖/存活信号通路，从而抑制肿瘤细胞增殖、诱导凋亡。分子结构通过平衡亲脂/亲水性、降低被P-gp/BCRP外排的几率，血脑屏障穿透能力强，对脑转移病灶控制突出。适应症二线（2024-05-20获批）：既往经EGFR-TKI治疗时或治疗后疾病进展，且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性NSCLC成人患者。一线（2024-11获批）：EGFR外显子19缺失或外显子21（L858R）置换突变的局部晚期或复发转移性NSCLC成人患者。竞品分析：国内已上市的8款第三代EGFR-TKI为奥希替尼、阿美替尼、伏美替尼、贝福替尼、瑞齐替尼、瑞厄替尼、利厄替尼、兰泽替尼。上市情况获批信息上市信息注册与受理信息临床试验信息研发状态及关键临床数据专利情况其他药品分享链接如下，欢迎点击查看： Ormeloxifene OTF慢性体重管理的新型药物-Tirzepatide 新型的非阿片类小分子镇痛药-Suzetrigine 奥麦利昔芬口腔薄膜立项调研报告纳米技术双氯芬酸乳胶剂药学研究 2025年9月药品批准信息快讯（八）——利斯的明透皮贴剂分享 2025年9月药品批准信息快讯（九）——米托坦片分享 CDE-《化学仿制药参比制剂目录（第一百批）》（征求意见稿）[附: 药品分享——阿达苏(洛沙平吸入剂)] 药品分享-塞来昔布盐酸曲马多片药品分享——伐莫洛龙口服混悬液【药品分享】盐酸菲优拉生片【药品分享】拉坦噻吗滴眼液【药品分享】Baxdrostat 片【药品分享】Omecamtiv Mecarbil缓释片【药品分享】曲地匹坦（Rolapitant）【药品分享】Zasocitinib 胶囊【药品分享】甲磺酸阿帕替尼片【药品分享】巴氯芬口服溶液【药品分享】奥德昔巴特胶囊【药品分享】扎维吉泮鼻喷雾剂【药品分享】左羟丙哌嗪糖浆【药品分享】利丙双卡因凝胶贴膏【药品分享】司来吉兰改良型新药（缓释片）【药品分享】复方甘菊利多卡因凝胶【药品分享】盐酸索安非托片【药品分享】地塞米松口溶膜【药品分享】盐酸来罗西利片【药品分享】马来酸噻吗洛尔凝胶【药品分享】褪黑素颗粒【药品分享】罗氟司特乳膏【药品分享】盐酸芬戈莫德胶囊【药品分享】示踪用盐酸米托蒽醌注射液【药品分享】美洛昔康纳米晶注射液【药品分享】Clasoterone 5%外用溶液【药品分享】马来酸依那普利口服溶液【药品分享】注射用双氯芬酸钠利多卡因【药品分享】马来酸依那普利叶酸片—复方降压药【药品分享】依曲帕米鼻喷雾剂—用于治疗成人阵发性室上性心动过速的可自行给药鼻喷雾剂【药品分享】奥卡西平口服混悬液—一款可用于儿童的钠通道调节类抗癫痫药【药品分享】泊沙康唑口服混悬液——一种常用的抗真菌药物【药品分享】舒沃替尼片【药品分享】依伏卡塞片——第二代口服拟钙剂【药品分享】西诺氨酯片——第三代抗癫痫发作药物【药品分享】匹妥布替尼片——非共价可逆 BTK 抑制剂（用于复发 / 难治套细胞淋巴瘤（MCL））【药品分享】贝美前列素【产品分享】达普司他片【药品分享】水合氯醛糖浆——镇静催眠药【产品分享】苏沃雷生（Suvorexant）——全球首个食欲素受体拮抗剂类催眠药【药品分享】贝沙罗汀【药品分享】地夫可特干混悬剂——一种糖皮质激素类药物【药品分享】伊卢多啉片——治疗成人腹泻型肠易激综合征（IBS‑D）的首创口服阿片受体调节剂【药品分享】卢美哌隆胶囊——一种新型的非典型抗精神病药物【药品分享】奥氟格列隆片——口服非肽类小分子 GLP-1 受体激动剂【药品分享】苯磺酸克利加巴林胶囊——一种新型的治疗神经病理性疼痛的药物【药品分享】苯磺酸美洛加巴林片——治疗周围神经病理性疼痛（PNP）的第三代钙离子通道调节剂【药品分享】Iberdomide胶囊——一款新一代cereblon（CRBN）E3连接酶调节剂（CELMoD）化合物【药品分享】酒石酸伐尼克兰鼻喷雾剂——一种用于治疗干眼症的西药【药品分享】赛沃替尼片——中国首个获批的高选择性 MET 酪氨酸激酶抑制剂【药品分享】盐酸阿夫唑嗪缓释片——一种用于治疗良性前列腺增生（BPH）的 α1 - 受体阻滞剂【药品分享】索格列净片——全球首个获批的SGLT1/SGLT2 双重抑制剂【药品分享】奥吡卡朋胶囊——新一代的儿茶酚-氧位-甲基转移酶抑制剂（COMT）【药品分享】奎扎替尼片——一种口服高选择性 FLT3 抑制剂【药品分享】硫酸拉罗替尼胶囊 / 口服溶液——全球首个高选择性口服 TRK 抑制剂【药品分享】司帕生坦片——成人IgA肾病领域首个非免疫抑制疗法【药品分享】黄体酮阴道栓剂/阴道缓释凝胶剂——主要用于辅助生殖技术（ART）中的黄体支持【药品分享】替戈拉生片——首款国产钾离子竞争性酸阻滞剂类药物（P-CAB）【药品分享】拉坦前列烯酯滴眼剂——一种新型眼科用药【药品分享】布比卡因脂质体注射液——一种长效局部麻醉药【药品分享】甲磺酸加诺沙星片——一种喹诺酮类抗菌药【药品分享】磷酸芦可替尼乳膏——中国首款且唯一获批的白癜风治疗靶向药【药品分享】甲磺酸洛美他派胶囊——全球唯一口服MTP抑制剂【药品分享】依达拉奉口服混悬液——肌萎缩侧索硬化症（ALS，渐冻人症）新药【药品分享】依达拉奉右莰醇舌下片——全球卒中领域首个获FDA突破性疗法认定的舌下脑保护剂【药品分享】马来酸氟诺替尼片——JAK2/FLT3/CDK6 三靶点抑制剂【药品分享】普拉替尼胶囊——国内首个获批的高选择性 RET（转染重排）酪氨酸激酶抑制剂【药品分享】右美托咪定舌下膜——新型 α₂肾上腺素受体激动剂舌下膜剂【药品分享】卡匹色替片——全球首个获批上市的AKT抑制剂【药品分享】库莫西利胶囊——全球首个CDK2/4/6抑制剂【药品分享】赛贝曲司他片——全球首个HAE急性发作口服疗法【药品分享】KYGEVVI（Doxecitine/Doxribtimine）——全球首款且唯一获批的TK2d针对性治疗药物【药品分享】Forzinity（Elamipretide）注射剂——全球首个用于治疗Barth综合征的药物【药品分享】Brinsupri（Brensocatib, 布伦索卡替布）片——全球首个获批上市的二肽基肽酶1（DPP-1）抑制剂【药品分享】维立西呱片——全球首个心衰适应症的可溶性鸟苷酸环化酶（sGC）刺激剂【药品分享】盐酸哌罗匹隆片——非典型抗精神病药【药品分享】盐酸托泊替康胶囊/注射用盐酸托泊替康——经典的拓扑异构酶Ⅰ抑制剂类抗肿瘤药【药品分享】阿普昔腾坦片——全球首个获批用于难治性高血压的口服双重内皮素受体拮抗剂（ERA）【药品分享】注射用盐酸依拉环素——全球首个氟环素类抗生素【药品分享】奥洛格列净胶囊——国内首款抑制SGLT1与SGLT2的1类创新药【药品分享】盐酸匹米替尼胶囊——国内首个、全球首个获批的腱鞘巨细胞瘤（TGCT）系统性靶向药，高选择性CSF-1R抑制剂【药品分享】布地奈德肠溶胶囊——全球首个、中国唯一获批用于原发性IgA肾病对因治疗的靶向药物【药品分享】艾拉莫德片——中国原研、全球首个上市的小分子抗风湿药（csDMARD）【药品分享】索托克拉片——新一代BCL2抑制剂【药品分享】利奈昔巴特片——口服、选择性、可逆性回肠胆汁酸转运体（IBAT/ASBT）抑制剂【药品分享】多替诺雷片——高选择性URAT1抑制剂【药品分享】瑞普泊肽片——口服GLP‑1/GIP双靶点激动剂【药品分享】硫酸索西美雷塞片——口服、强效的KRAS G12C共价抑制剂【药品分享】罗伐昔替尼片——全球首创JAK/ROCK双靶点口服小分子抑制剂【药品分享】埃诺格鲁肽注射液——全球首个获批上市的cAMP偏向型长效GLP-1受体激动剂【药品分享】维培那肽注射液——长效GLP-1受体激动剂【药品分享】普乐司兰钠注射液——全球首个靶向APOC3 mRNA的siRNA降脂药【药品分享】玛仕度肽注射液——全球首个GCG/GLP-1双激动剂【药品分享】瑞米布替尼片——全球首个获批用于CSU的口服靶向药【药品分享】溴莫尼定噻吗洛尔滴眼液——α₂受体激动剂与非选择性 β 受体阻滞剂组成的复方降眼压药【药品分享】吡洛西利片——国内首个CDK2/4/6多靶点抑制剂【药品分享】奥氟格列隆片（Orforglipron） ——中国首个、全球首批上市的口服小分子 GLP-1受体激动剂【药品分享】Copper Histidine注射液（Zycubo）——全球首个、唯一用于治疗儿童门克斯病（Menkes disease）的铜替代注射剂【药品分享】依来格列隆片（Elecoglipron）——口服小分子非肽类GLP-1受体激动剂【药品分享】阿利奈普仑（Aleniglipron）——口服小分子、非肽类、偏向性GLP-1受体激动剂【药品分享】甲磺酸阿美替尼片——中国首个原研三代EGFR酪氨酸激酶抑制剂（TKI）【药品分享】甲磺酸达麦利替尼片——口服高选择性c-MET酪氨酸激酶抑制剂【药品分享】盐酸Acoramidis片——转甲状腺素蛋白（TTR）稳定剂【药品分享】阿莫西林伏诺拉生胃漂浮片——3D打印胃漂浮片【药品分享】盐酸伊可白滞素片——全球首创口服IL‑23受体拮抗剂【药品分享】马来酸吡咯替尼片——中国首个自研的HER1/HER2/HER4不可逆酪氨酸激酶抑制剂（TKI）【药品分享】本维莫德乳膏——全球首创芳香烃受体（AhR）调节剂（TAMA）类皮肤病外用药【药品分享】盐酸莫托咪酯注射液——化药1类静脉麻醉新药【药品分享】注射用罗哌卡因微晶——长效缓释局部麻醉药【药品分享】盐酸伊立替康脂质体注射液——一款针对吉西他滨治疗失败的转移性胰腺癌的二线标准脂质体化疗药【药品分享】甲磺酸氟马替尼片——Bcr-Abl酪氨酸激酶选择性抑制剂【药品分享】注射用阿加糖酶β——国内获批的首个用于治疗法布雷病的药物【药品分享】甲苯磺酸尼拉帕利胶囊——高选择性PARP1/2抑制剂【药品分享】帕米帕利胶囊——强效、选择性PARP1/2抑制剂【药品分享】苯环喹溴铵鼻喷雾剂——选择性M胆碱能受体拮抗剂【药品分享】注射用拉罗尼酶浓溶液——MPS Ⅰ型的特异性酶替代治疗药物【药品分享】海博麦布片——国产自主原研的胆固醇吸收抑制剂【药品分享】盐酸可洛派韦胶囊——直接抗病毒药物（DAA）→ NS5A抑制剂【药品分享】克拉考特酮乳膏——外用、非甾体、选择性雄激素受体（AR）抑制剂【药品分享】非卢替尼片——全球首个用于多发性硬化的口服BTK抑制剂【药品分享】Brenipatide注射液——GLP-1R/GIPR双受体激动剂（继替尔泊肽之后的第二款）【药品分享】罗赛促红素α注射液——国产首个长效重组促红细胞生成素（EPO）创新药【药品分享】贝组替凡片——全球首个口服小分子HIF-2α抑制剂【药品分享】那米司特片——口服选择性PDE4B抑制剂【药品分享】富马酸立康可泮胶囊——一款针对罕见病PNH的口服补体B因子抑制剂【药品分享】醋酸索乐匹尼布片——高选择性脾酪氨酸激酶（Syk）抑制剂【药品分享】甲磺酸艾多替尼片——全球首款专为肺癌脑转移设计的第三代EGFR-TKI 【药品分享】安瑞克芬注射液——全球首个获批镇痛适应症的高选择性外周κ-阿片受体（KOR）激动剂【药品分享】Difelikefalin注射液——全球首个获批的外周选择性κ-阿片受体（KOR）激动剂【药品分享】Obefazimod——口服、靶向 CBC、特异性增强miR-124的首创小分子【药品分享】拉尼兰诺片——口服泛PPAR激动剂【药品分享】舒洛地特注射液——抗血栓药、血管保护剂【药品分享】贝普若韦生注射液——反义寡核苷酸（ASO）类乙肝新药【药品分享】氨酚右敏口服溶液（奥肯能®）——中国内地唯一获批的氨酚右敏口服溶液【药品分享】佩玛贝特片——新型过氧化物酶体增殖物激活受体α/δ双重激动剂 (PPARα/δ) 【药品分享】盐酸依匹斯汀乳膏——外用第二代非镇静抗组胺抗过敏药膏【药品分享】注射用双羟萘酸帕瑞肽微球——一款用于治疗肢端肥大症的第二代长效生长抑素类似物（SRL）微球制剂【药品分享】埃拉菲布拉诺片——治疗原发性胆汁性胆管炎（PBC）的口服靶向新药【药品分享】泽卢克布仑钠注射液——新一代皮下注射型C5补体抑制剂【药品分享】依达拉奉右莰醇注射用浓溶液——一款复方神经保护类注射剂【药品分享】醋酸戈那瑞林注射液——促性腺激素释放激素（GnRH）类药物【药品分享】甲磺酸贝舒地尔片——全球首个选择性ROCK2激酶抑制剂【药品分享】伊托法替布软膏——外用JAK抑制剂（JAK1/JAK3）【药品分享】注射用华卟啉钠——新型肿瘤光动力治疗（PDT）专用光敏剂【药品分享】优替德隆胶囊——口服埃博霉素类微管抑制剂【药品分享】艾普美妥司他片——EZH1/2双靶创新药【药品分享】精氨酸艾曲莫德片——新型选择性鞘氨醇1-磷酸受体（S1P₁）调节剂【药品分享】磷酸芦可替尼乳膏——全球/国内首款、唯一获批用于非节段型白癜风复色的外用JAK1/JAK2选择性抑制剂【药品分享】盐酸右哌甲酯缓释胶囊——治疗6岁及以上注意缺陷多动障碍（ADHD）的一线药物【药品分享】抗菌肽PL-3301口腔凝胶——中国首创的抗菌肽类抗口腔真菌感染药物【药品分享】Zasocitinib (TAK-279) 胶囊——新一代高选择性口服 TYK2 抑制剂【药品分享】注射用Abelacimab——一款全人源IgG1单克隆抗体，靶向凝血因子XI（FXI）【药品分享】Duvakitug注射液——首创性人源化IgG1-λ2单克隆抗体，靶向TL1A（TNFSF15）【药品分享】醋酸氟轻松/氢醌/维A酸乳膏——治疗中重度黄褐斑疗效明确的外用复方【药品分享】富马酸伏诺拉生氯化钠注射液——钾离子竞争性酸阻滞剂（P‑CAB）||东阳光药业研发的2.2,2.4类改良新型新药【药品分享】盐酸阿曲生坦片——诺华研发的高选择性内皮素 A（ETA）受体拮抗剂||中国首个获批用于IgA 肾病的非免疫性口服靶向药【药品分享】RGT-274-CR胶囊——上海齐鲁锐格医药研发的口服小分子GLP-1受体激动剂【药品分享】酒石酸西尼必利片——高选择性5-HT₄受体激动剂类胃肠动力药【药品分享】石杉碱甲控释片——采用双相控释/渗透泵技术的2.2类改良型新药【药品分享】塞伐艾替尼片——口服、可逆、选择性酪氨酸激酶抑制剂（TKI）【药品分享】Admilparant片——口服小分子LPA₁受体拮抗剂【药品分享】瑞拉可兰胶囊——全球首个选择性糖皮质激素受体（GR）拮抗剂【药品分享】盐酸依特卡肽注射液——全球首个、国内唯一获批的静脉注射型拟钙剂【药品分享】Avacincaptad pegol玻璃体内注射液——全球首批用于AMD继发地图样萎缩（GA）的靶向药物【药品分享】盐酸达利雷生片——新一代非管制、非苯二氮䓬类抗失眠药物【药品分享】甲磺酸瑞索利塞片——高选择性PI3Kα小分子靶向抑制剂 || 全球首个获批用于特定卵巢癌的靶向新药【药品分享】富马酸西他沙星注射液——新型喹诺酮类抗菌药物【药品分享】Icotrokinra——全球首个获批的口服 IL-23 受体（IL-23R）选择性拮抗多肽【药品分享】氘可来昔替尼片（Deucravacitinib）——全球首个口服、选择性 TYK2 变构抑制剂【药品分享】柯美奇拜单抗注射液——鼻用糖皮质激素治疗后症状控制不佳的成人中重度季节性过敏性鼻炎患者的福音【药品分享】吉诺昔替尼——口服小分子JAK1/TYK2双重抑制剂【药品分享】洛替拉纳（Lotilaner）——GABA 门控氯离子通道非竞争性拮抗剂 || 兼具兽医驱虫与人用眼科两大用途【药品分享】CagriSema——由卡格列肽（cagrilintide）2.4 mg与司美格鲁肽（semaglutide）2.4 mg组成的强效减重复方药【药品分享】苹果酸卡博替尼——口服、多靶点酪氨酸激酶抑制剂（TKI）【药品分享】迪高替尼（Delgocitinib）——一款外用泛JAK抑制剂【药品分享】拉氟莫司(Laflunimus)——口服免疫抑制剂 || 兼具免疫抑制与抗炎双重活性【药品分享】伏昔尼布片——全球首个IDH1/IDH2双重突变抑制剂靶向药【药品分享】盐酸奥昔布宁片——M受体抗胆碱药【药品分享】贝泽昔替尼片——国内首款获批的高选择性JAK2单靶点抑制剂【药品分享】苯甲酸安达艾替尼胶囊——新型小分子酪氨酸激酶不可逆抑制剂（EGFR-TKI）【药品分享】伏欣奇拜单抗注射液——全人源抗IL‑1β单克隆抗体 || 用于急性痛风性关节炎的1类创新生物药【药品分享】利多卡因丁卡因乳膏【药品分享】伐米奇拜单抗注射液——玻璃体内注射用抗IL-6人源化单抗【药品分享】依赛弗酶α注射液（Efzimfotase alfa 注射液）——第二代重组组织非特异性碱性磷酸酶（TNSALP）酶替代疗法【药品分享】格达托利西布（Gedatolisib）——first‑in-class 泛 PI3K/mTORC1/2 双重抑制剂【药品分享】伯瑞替尼肠溶胶囊——中国原研、高选择性c-MET小分子抑制剂 || 首个获批MET扩增NSCLC单药治疗的靶向药【药品分享】力胜克拉片——中国首个申报上市的原研Bcl-2抑制剂、全球第二款Bcl-2抑制剂【药品分享】BGM0504注射液——GLP-1/GIP 双受体激动剂【药品分享】塞利尼索片——全球首个口服选择性核输出蛋白XPO1抑制剂【药品分享】Seltorexant薄膜包衣片——选择性食欲素2受体（OX2R）高选择性拮抗剂【药品分享】盐酸埃克替尼片——国内首个自主研发的一代EGFR-TKI 【药品分享】盐酸伊普可泮胶囊——全球首个口服补体B因子抑制剂【药品分享】恩考芬尼胶囊——靶向BRAF V600突变的口服激酶抑制剂【药品分享】Enpatoran——口服、选择性TLR7/8小分子抑制剂【药品分享】硝酸异康唑阴道片——抗真菌外用药物【药品分享】Zorevunersen注射液——全球独家ASO上调蛋白表达技术【药品分享】妥拉美替尼胶囊——全球首个针对NRAS突变黑色素瘤的MEK抑制剂【药品分享】盐酸替那帕诺片——全球首创NHE3抑制剂类新型降磷药物【药品分享】注射用莱古比星——新型蒽环类抗肿瘤药【药品分享】优替德隆胶囊——口服埃博霉素类微管抑制剂【药品分享】伊那利塞片——中国首个PIK3CA突变乳腺癌精准靶向药【药品分享】呋喹替尼胶囊——中国首个自主研发VEGFR-TKI || VEGFR靶点靶向抗癌药【药品分享】琥珀酸瑞波西利片——CDK4/6抑制剂【药品分享】盐酸替那帕诺片——全球首个且唯一获批的肠道磷吸收抑制剂【药品分享】芬布替尼片——口服、可逆、可透过血脑屏障的BTK抑制剂【药品分享】炔丙基半胱氨酸胶囊——全球首个进入临床的硫化氢（H₂S）供体I类创新药【药品分享】Balcinrenone达格列净胶囊——选择性盐皮质激素受体拮抗剂（MRA）+SGLT-2抑制剂【药品分享】诺拉西班（Nolasiban）分散片——选择性口服催产素受体拮抗剂 || 早产二线/辅助治疗药物【药品分享】塞多明基注射液——国内首款裸质粒基因治疗药物【药品分享】鲁兹诺雷钠片——国产首个高选择性URAT1抑制剂【药品分享】玛伐凯泰胶囊——全球首创、中国唯一获批的心肌肌球蛋白抑制剂【药品分享】依托芬那酯凝胶——外用非甾体抗炎镇痛药【药品分享】聚卡波非钙片——国际指南首选容积性缓泻剂【药品分享】Mezigdomide胶囊——新一代IMiDs/cereblon E3泛素连接酶调节【药品分享】洛布替尼片——全球首款共价+非共价双机制第四代 BTK 靶向药【药品分享】奥莱泊肽注射液——PEG修饰长效GLP‑1单靶点激动剂【药品分享】安瑞曲替尼胶囊 ——国内第二款国产二代NTRK广谱抗癌药【药品分享】麦格司他胶囊——抑制葡萄糖神经酰胺合成酶的罕见病口服靶向药【药品分享】乌帕替尼片（Upadacitinib）——选择性JAK1抑制剂【药品分享】Dordaviprone胶囊——全球首款、目前唯一获批用于 H3 K27M 突变型弥漫性中线胶质瘤（DMG）的靶向药【药品分享】屈昔多巴胶囊——去甲肾上腺素前体药物 || 帕金森、多系统萎缩、神经源性体位低血压一线对症用药【药品分享】康特替尼颗粒——第二代ALK多靶点激酶抑制剂【药品分享】盐酸兰诺可泮片——国产首个获批上市的补体因子B（CFB）抑制剂【药品分享】Elinzanetant软胶囊——全球首款NK1/NK3双重神经激肽受体拮抗剂【药品分享】Fosmanogepix注射液——全球首创（First-in-class）Gwt1抑制剂类抗真菌前药【药品分享】Zorevunersen注射液——反义寡核苷酸药物【药品分享】宗艾替尼片——高选择性不可逆HER2（ERBB2）酪氨酸激酶抑制剂（TKI）【药品分享】甲苯磺酸他拉唑帕利胶囊——高选择性PARP抑制剂【药品分享】Bexicaserin口服溶液——选择性5-HT2C受体激动剂口服液体制剂【药品分享】醋酸伏诺拉生注射用浓溶液——钾离子竞争性酸阻滞剂（P-CAB）【药品分享】甲苯磺酸依仑司群片——新一代口服选择性雌激素受体降解剂（SERD）【药品分享】硫酸瑞美吉泮口崩片——CGRP 受体拮抗剂（降钙素基因相关肽）|| 偏头痛靶向特效药【药品分享】阿托吉泮片——全球首款口服长效CGRP靶点预防偏头痛药物【药品分享】乌布吉泮片——CGRP受体拮抗剂 || 第二代口服偏头痛急性期药物【药品分享】扎维吉泮鼻喷雾剂——高选择性CGRP受体拮抗剂 || 全球唯一获批鼻喷CGRP吉泮类急性期药物【药品分享】培来加南喷雾剂——全球首款上市加南类多肽抗菌药（FIC）【药品分享】艾沙利酮片——高选择性非甾体醛固酮受体拮抗剂（MRA） || 全球首个上市的非甾体选择性MR拮抗剂【药品分享】布美他尼鼻喷雾剂——全球首款、唯一鼻内给药袢利尿剂【药品分享】注射用盐酸依拉环素——新型全合成氟环素类（四环素衍生物）静脉抗生素【药品分享】舒瑞基奥仑赛注射液——全球首款实体瘤自体CLDN18.2靶向CAR-T细胞新药【药品分享】盐酸环喷托酯滴眼液——儿童验光首选短效睫状肌麻痹剂之一【药品分享】盐酸赛庚啶口服溶液——抗过敏抗组胺药【药品分享】Rinzimetostat (ORIC-944)——口服选择性 EED别构型PRC2表观遗传抑制剂【药品分享】Empasiprubart注射用浓溶液——全球首创靶向补体C2人源化IgG1清扫型单克隆抗体【药品分享】阿更葡糖钠注射液——全球第二款、中国首款自主研发的环糊精类靶向肌松逆转剂【药品分享】盐酸罗哌卡因缓释溶液——国产自主长效局麻缓释制剂 || 填补国内切口原位长效镇痛空白【药品分享】Telisotuzumab Adizutecan 注射用粉末——抗c-Met抗体偶联药物（ADC）【药品分享】L606 (曲前列尼尔脂质体吸入混悬液)——靶向肺动脉高压【药品分享】佩米替尼片——选择性FGFR1/2/3酪氨酸激酶抑制剂【药品分享】唑尼沙胺胶囊——磺酰胺类结构 || 广谱抗癫痫药，偏头痛预防【药品分享】琥珀酸安维吖啶片——双靶点胆碱酯酶抑制剂【药品分享】布莱昔替尼片（Bleximenib）——口服高选择性Menin-KMT2A相互作用抑制剂【药品分享】利厄替尼片——第三代EGFR-TKI靶向药【药品分享】注射用苯磺酸瑞马唑仑——苯二氮䓬类短效静脉镇静/麻醉药【药品分享】瑞维鲁胺片——国产全新二代雄激素受体抑制剂【药品分享】塞普替尼胶囊——全球首款高选择性RET靶向药 || 国内唯一拥有12岁以上儿童甲状腺肿瘤完整临床证据的RET抑制剂【药品分享】注射用和厚朴酚脂质体冻干粉——全球首创小分子脂质体靶向制剂【药品分享】注射用顺铂聚合物胶束——前沿纳米化疗创新赛道 || 改良型新药-纳米靶向注射制剂【药品分享】奥普雷顿片——国内首个获批的口服OX2R选择性激动剂【药品分享】琥珀酸思普可泮片——口服选择性补体B因子（CFB/FB）小分子抑制剂 || 全球首个每日一次口服FB抑制剂【药品分享】苹果酸法米替尼胶囊——多靶点TKI创新药 || 国内唯一获批用于宫颈癌的口服抗血管TKI 【药品分享】盐酸伊普可泮胶囊【药品分享】枸橼酸伊沙佐米胶囊——第二代、全球首个口服可逆性蛋白酶体抑制剂【药品分享】注射用西罗莫司（白蛋白结合型）——mTOR 激酶抑制剂 || 白蛋白纳米粒递送系统【药品分享】Bleximenib片——Menin抑制剂（KMT2A/Menin 相互作用抑制剂）【药品分享】Eloralintide注射液——选择性长效胰淀素（Amylin）受体激动剂（AMY1R激动剂）【药品分享】阿柏西普眼内注射溶液——重组人源VEGF融合蛋白的治疗用生物制品【药品分享】艾托莫德片——高选择性S1PR1（鞘氨醇‑1‑磷酸受体1）小分子激动剂【药品分享】GBI268注射液——复方局部镇痛注射剂【药品分享】Edecesertib片——IRAK‑4小分子激酶抑制剂【药品分享】阿布昔替尼片——高选择性JAK‑1小分子抑制剂【药品分享】盐酸阿思尼布片——全球首个且目前唯一基于ABL肉豆蔻酰口袋（STAMP）创新机制的靶向药物【药品分享】Venglustat——葡萄糖神经酰胺合成酶（GCS/UGCG）抑制剂【药品分享】塞瑞替尼胶囊——第二代ALK酪氨酸激酶抑制剂（ALK-TKI）【药品分享】泊那替尼片——第三代BCR-ABL酪氨酸激酶抑制剂（TKI）|| 唯一能够有效抑制BCR‑ABL T315I耐药突变的TKI 【药品分享】盐酸阿那格雷胶囊——PDE3抑制剂【药品分享】奥雷巴替尼片——国内首个获批可有效抑制T315I突变的三代BCR-ABL抑制剂【药品分享】比克恩丙诺片——HIV‑1感染单片复方抗病毒药【药品分享】甲磺酸奥希替尼片——第三代EGFR靶向药【药品分享】醋酸戈舍瑞林缓释植入剂——促性腺激素释放激素激动剂缓释皮下植入制剂【药品分享】拉考沙胺缓释胶囊——钠通道调节剂【药品分享】纳曲酮利培酮植入剂——新的缓释植入剂型【药品分享】普那布林注射用浓溶液——GEF‑H1（ARHGEF2）激动剂【药品分享】Petrelintide注射液——长效胰淀素（Amylin）受体激动剂【药品分享】酒石酸凡瑞格拉替尼片——1类高选择性FGFR口服小分子创新药【药品分享】醋酸兰瑞肽缓释注射液（预充式）——长效生长抑素类似物（SSA）【药品分享】吡非尼酮胶囊——多细胞因子通路调节剂【药品分享】罗替高汀贴片——非麦角类多巴胺受体激动透皮贴剂 || 全球首个经皮吸收的帕金森治疗药物【药品分享】芦沃美替尼片——高选择性MEK1/2（丝裂原活化蛋白激酶激酶 1/2）抑制剂【药品分享】硫酸阿托品滴眼液——竞争性 M‑胆碱（毒蕈碱）受体拮抗剂【药品分享】盐酸恩沙替尼胶囊——国产第二代间变性淋巴瘤激酶(ALK)-酪氨酸激酶抑制剂(TKI)靶向药【药品分享】富马酸奥赛利定注射液——新型静脉镇痛药物 || G蛋白偏向性μ‑阿片受体激动剂【药品分享】司美格鲁肽微针贴片——用于2型糖尿病与肥胖体重管理的新剂型药品【药品分享】甲苯磺酸利特昔替尼胶囊——国内首个获批可用于12–17岁青少年重度斑秃的口服系统治疗药物【药品分享】艾曲帕米鼻喷雾剂——经鼻给药的速效钙通道阻滞剂【药品分享】盐酸替扎尼定胶囊——中枢性α2肾上腺素受体激动剂【药品分享】格贝前列素滴眼液——单分子双功能NO供体型前列腺素前药【药品分享】盐酸伊司特韦片——全球首个依托DEL结合AI技术成功获批的原创小分子药物【药品分享】布格替尼片——口服小分子ALK酪氨酸激酶抑制剂【药品分享】司来帕格片——口服选择性前列腺素受体（IP受体）激动剂【药品分享】甲磺酸伏美替尼片——国产第三代EGFR靶向药（EGFR-TKI）【药品分享】帕替罗姆山梨醇钙干混悬剂——不吸收入血的口服阳离子交换聚合物类新型降钾药物【药品分享】塞拉维诺片——CCR5（C-C 趋化因子受体 5）拮抗剂【药品分享】盐酸西替利嗪滴眼液——局部抗组胺滴眼液 || 高选择性 H₁组胺受体拮抗剂（第二代抗组胺）【药品分享】注射用莱古比星——全球首创的小分子偶联化疗药【药品分享】尤帕卡塞钠注射液——CaSR钙敏感受体正向变构调节剂【药品分享】马来酸依格美妥司他片——口服小分子EZH2表观遗传抑制剂【药品分享】Laroprovstat瑞舒伐他汀片——口服小分子 PCSK9 抑制剂【药品分享】利扎布替尼片（Rilzabrutinib片）——全球首款获批用于ITP的BTK抑制剂【药品分享】Trontinemab注射液——罗氏Brainshuttle™平台开发的2+1型双特异性IgG1抗体【药品分享】Risankizumab注射液——人源化IgG1单克隆抗体【药品分享】Zasocitinib (TAK-279) 片——口服小分子别构TYK2抑制剂【药品分享】双氯芬酸依泊胺凝胶贴膏——全新活性成分凝胶贴膏 || 美国首个获批的NSAID外用凝胶贴膏【药品分享】拉索昔芬片——第三代选择性雌激素受体调节剂（SERM）【药品分享】苯丁酸氮芥片——非靶向细胞毒烷化剂【药品分享】达依泊汀α注射液——第二代长效重组促红细胞生成素（ESA，红细胞生成刺激剂）【药品分享】Ferric Bepectate IV Injection——静脉用三价铁胶体补铁制剂【药品分享】Momelotinib片——口服ATP竞争性激酶抑制剂【药品分享】富马酸氯马斯汀注射液——第一代乙醇胺类（二苯甲醚类）H₁受体拮抗剂【药品分享】雌二醇透皮喷雾剂——雌激素受体ERα（ESR1）和ERβ（ESR2）【药品分享】Cemdisiran注射液——肝靶向GalNAc偶联小干扰RNA（siRNA）【药品分享】诺吉仑赛注射液——国内首款递交上市申请的TIL产品免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。

上市批准申请上市专利到期

100 项与马来酸吡咯替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XE L01E	DB14993

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期 HER2 阳性乳腺癌	中国	江苏恒瑞医药股份有限公司	2023-04-17
HER2阳性乳腺癌	中国	江苏恒瑞医药股份有限公司	2018-08-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2低表达乳腺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2024-01-17
HR阳性乳腺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2024-01-17
HR阳性/HER2低表达乳腺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2024-01-17
浸润性乳腺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2024-01-17
晚期非小细胞肺癌	临床3期	美国	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	澳大利亚	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	比利时	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	法国	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	德国	江苏恒瑞医药股份有限公司	2020-09-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2026	N/A	晚期 HER2 阳性乳腺癌 HER2-positive	67	Inetetamab combined with Pyrotinib	鹽壓繭衊膚鹽淵繭構簾(願獵鏇觸獵選簾蓋製艱) = 獵夢簾觸鬱廠構簾製糧夢淵蓋遞壓範淵鏇壓簾 (觸餘衊夢觸網鏇糧鏇窪, 16.05 ~ 29.53) 更多	积极	2026-10-23
				Inetetamab combined with Pyrotinib (first- or second-line therapy)	鹽壓繭衊膚鹽淵繭構簾(願獵鏇觸獵選簾蓋製艱) = 積糧鬱糧醖襯鹽蓋糧蓋夢淵蓋遞壓範淵鏇壓簾 (觸餘衊夢觸網鏇糧鏇窪, 21.5 ~ 34.5)
ESMO2026	N/A	晚期 HER2 阳性乳腺癌一线 HER2-positive	9,187	THPyro	窪築鹽齋夢淵膚廠夢壓(鹽繭遞鏇鬱繭鹹願簾築) = 築壓構膚蓋繭簾廠製鹹糧繭鬱積構繭獵顧鑰窪 (觸鬱淵獵願積夢艱窪憲 )	积极	2026-10-23
				T-DXd+P	窪築鹽齋夢淵膚廠夢壓(鹽繭遞鏇鬱繭鹹願簾築) = 觸鏇觸齋窪醖蓋蓋鑰衊糧繭鬱積構繭獵顧鑰窪 (觸鬱淵獵願積夢艱窪憲 )
NCT06832904 (NEOTORCH-BREAST05, ESMO2026)	临床2期	HER2阳性乳腺癌新辅助 HER2-positive	38	Neoadjuvant chemotherapy + Pyrotinib + trastuzumab	鹽繭積繭艱鏇願鏇獵襯(鹽顧餘簾築遞壓餘積襯) = diarrhea (29, 76.3%) 範蓋窪選範選製淵範鹽 (壓願襯選廠艱網艱鏇壓 ) 更多	积极	2026-10-23
CSCO2026	N/A	HER2阳性乳腺癌 HER2-positive	251	Pyrotinib plus upfront RT	壓糧廠選廠襯憲醖糧衊(積遞簾構壓憲網網鏇獵): HR = 0.6 (95.0% CI, 0.41 ~ 0.86), P-Value = 0.006 更多	积极	2026-09-11
				Pyrotinib monotherapy
CSCO2026	N/A	晚期 HER2 阳性乳腺癌一线 HER2-positive	143	Pyrotinib plus Trastuzumab and a taxane (PyHT)	願顧糧憲觸襯繭鬱餘觸(顧鬱願顧淵鹹夢窪夢構) = 齋網構鑰壓製鏇醖艱鹽壓獵積願範築選窪鏇廠 (餘糧膚鑰選糧遞鬱選顧 ) 更多	积极	2026-09-11
				Pertuzumab plus Trastuzumab and a taxane (THP)	願顧糧憲觸襯繭鬱餘觸(顧鬱願顧淵鹹夢窪夢構) = 構膚襯鑰鹽築醖憲鬱鑰壓獵積願範築選窪鏇廠 (餘糧膚鑰選糧遞鬱選顧 ) 更多
CSCO2026	N/A	HER2阳性乳腺癌新辅助 HER2 positive	63	Pyrotinib + Trastuzumab + liposomal doxorubicin + cyclophosphamide + nab-paclitaxel	窪遞積壓鹹醖網鬱鹹齋(齋觸願觸憲顧鹽鹽膚顧) = diarrhea (1.6%) and neutropenia (1.6%). 鏇憲窪願廠範糧廠鏇襯 (衊願廠壓糧鏇醖糧蓋鬱 ) 更多	积极	2026-09-11
				Pyrotinib + Trastuzumab + liposomal doxorubicin + cyclophosphamide + nab-paclitaxel (hormone receptor-negative)
NCT06234137 (neoPICD, ASCO_Breakthrough2026)	临床2期	局部晚期乳腺癌新辅助 HER2-positive	124	Inetetamab + Pyrotinib + Chemotherapy	齋繭夢淵壓憲糧遞繭淵(顧鹹鑰範衊觸製蓋廠積) = 築獵襯遞壓遞憲衊簾壓襯糧齋選獵觸鹹窪鬱鏇 (積齋網齋構襯遞淵醖膚, 87.6 ~ 97.6) 更多	积极	2026-06-25
				Inetetamab + Pyrotinib + Chemotherapy (HR-negative)	鹽積觸選簾廠憲遞鑰網(餘憲選網醖壓憲艱夢齋) = 膚夢蓋鏇窪繭壓積鏇艱獵鑰齋膚蓋淵範衊衊膚 (選憲鑰蓋遞築廠選製膚 ) 更多
NCT06495541 (ASCO2026)	N/A	晚期 HER2 阳性乳腺癌一线 HER2-positive	156	Pyrotinib (trastuzumab-naïve)	遞膚鬱廠壓廠鏇願襯鹽(鹹餘鹽淵蓋積淵網網鑰) = 獵壓顧淵淵夢簾遞鹽積襯鹹膚範顧餘憲襯蓋製 (蓋蓋鏇醖鏇鹽淵壓遞艱, 63.1 ~ 96.5) 更多	积极	2026-05-29
				Pyrotinib (trastuzumab-sensitive)	遞膚鬱廠壓廠鏇願襯鹽(鹹餘鹽淵蓋積淵網網鑰) = 獵顧醖簾簾鑰獵積築壓襯鹹膚範顧餘憲襯蓋製 (蓋蓋鏇醖鏇鹽淵壓遞艱, 78.5 ~ 100) 更多
ASCO2026	临床2期	HER2阳性转移性乳腺癌一线 \| 二线 HER2-positive	94	Inetetamab + Pyrotinib + Utidelone	繭網齋蓋鏇築鬱襯積憲(製淵鹹獵鬱遞範廠繭醖) = 膚膚範觸衊齋艱憲範餘鏇願構製衊憲憲選願鬱 (憲鬱襯鬱蓋範遞顧襯蓋, 72.6 ~ 89.8) 更多	积极	2026-05-29
NCT06483386 (ASCO2026)	临床2期	HER2阳性乳腺癌新辅助 HER2-positive	47	Pyrotinib+SC trastuzumab+capecitabine (HER2-positive early breast cancer)	醖憲鬱淵簾觸餘獵鏇積(鏇獵範淵顧艱廠鬱鏇獵) = 願膚繭憲淵窪餘願衊糧襯膚壓鹹鏇醖襯製窪顧 (襯製壓憲壓鹹觸鏇鏇鬱 ) 更多	积极	2026-05-29
				Pyrotinib+SC trastuzumab+capecitabine (ER negative, HER2 positive)	醖憲鬱淵簾觸餘獵鏇積(鏇獵範淵顧艱廠鬱鏇獵) = 鑰簾齋觸願襯鏇蓋憲簾襯膚壓鹹鏇醖襯製窪顧 (襯製壓憲壓鹹觸鏇鏇鬱 )